metformin has been researched along with Prediabetes in 228 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We conducted a Phase II double-blind placebo-controlled trial that aimed to determine the impact of metformin on blood glucose levels among people with prediabetes (defined as impaired fasting glucose [IFG] and/or impaired glucose tolerance [IGT]) and HIV in SSA." | 9.69 | Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial. ( Alam, U; Bates, K; Charles, G; Garrib, A; Jaffar, S; Kivuyo, S; Luo, H; Majaliwa, E; Mfinanga, S; Nyirenda, MJ; Ramaiya, K; Simbauranga, R; van Widenfelt, E; Wang, D, 2023) |
| "To investigate if addition of metformin to standard care (life-style advice) reduces the occurrence of cardiovascular events and death after myocardial infarction (MI) in patients with newly detected prediabetes." | 9.69 | Design and rationale of the myocardial infarction and new treatment with metformin study (MIMET) - Study protocol for a registry-based randomised clinical trial. ( Hagström, E; Hambraeus, K; James, S; Jernberg, T; Lagerqvist, B; Leosdottir, M; Lundman, P; Norhammar, A; Östlund, O; Pernow, J; Ritsinger, V, 2023) |
| " We aimed to explore 7% weight reduction rates of mazindol alone or combined with metformin in non-diabetic obese Mexican subjects who had additional risk factors for T2D." | 9.51 | Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects. ( Arguelles-Tello, FA; Barranco-Garduño, LM; Huerta-Cruz, JC; Kammar-García, A; Reyes-García, JG; Rocha-González, HI; Trejo-Jasso, CA, 2022) |
| "To evaluate the impact of concomitant use of probiotic BB-12 in metformin-treated patients with type 2 diabetes or prediabetes on glycemic control, metformin-related gastrointestinal side effects, and treatment compliance." | 9.51 | Metformin with Versus without Concomitant Probiotic Therapy in Newly Diagnosed Patients with Type 2 Diabetes or Prediabetes: A Comparative Analysis in Relation to Glycemic Control, Gastrointestinal Side Effects, and Treatment Compliance. ( Bostan, F; Çekin, AH; Kök, M; Köker, G; Özçelik Köker, G; Şahin, K; Şahintürk, Y; Uyar, S, 2022) |
| "To evaluate clinical efficacy of exenatide (EX), metformin (MET), or combination (COM) for prediabetes in PCOS." | 9.41 | Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study. ( Cai, J; Fan, W; Fu, JR; Gao, YN; Liu, W; Ma, JY; Sun, Y; Tao, T; Wang, YY; Xu, Y; Zhang, Y; Zhu, YC, 2021) |
| " placebo (H-HeFT) and 2) if metformin reduces the incidence of death, worsening heart failure, acute myocardial infarction, and stroke vs." | 9.41 | The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr ( Abdulla, J; Barasa, A; Bibby, BM; Bruun, NE; Brønnum-Schou, J; Bøtker, HE; Bøttcher, M; Dodt, K; Eiskjær, H; Gislason, G; Gustafsson, F; Hansen, VB; Hassager, C; Hollingdal, M; Høfsten, DE; Jonczy, B; Knudsen, AS; Kristensen, SL; Køber, L; Larsen, AH; Lomholdt, J; Madsen, JS; Mahboubi, K; Mellemkjær, S; Mikkelsen, KV; Møller, J; Nielsen, G; Nielsen, OW; Nørrelund, H; Poenaru, MP; Poulsen, MK; Raymond, I; Refsgaard, J; Schou, M; Serup-Hansen, K; Sillesen, K; Steffensen, FH; Torp-Petersen, C; Vraa, S; Wiggers, H, 2021) |
| "To assess the effects of dapagliflozin, metformin and exercise treatment on changes in plasma glucagon concentrations in individuals with overweight and HbA1c-defined prediabetes." | 9.41 | No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial. ( Amadid, H; Blond, MB; Bruhn, L; Clemmensen, KKB; Faerch, K; Holst, JJ; Jørgensen, ME; Karstoft, K; Persson, F; Quist, JS; Ried-Larsen, M; Torekov, SS; Vistisen, D; Wewer Albrechtsen, NJ, 2021) |
| "In this PROBE design trial, people who had recent stroke (within 3 months) with pre-diabetes were randomized to either the active arm (n = 13) receiving usual care plus Metformin XR (500 mg daily increased to a total daily dose of 1500 mg) or the control group receiving only usual care (n = 13)." | 9.41 | Feasibility trial of metformin XR in people with pre-diabetes and stroke (MIPPS)-randomised open blinded endpoint controlled trial. ( Borschmann, K; Churilov, L; Donnan, G; Ekinci, EI; Hachem, M; Lau, LH; Price, SAL; Sumithran, P; Tabesh, M; Thijs, V; Zajac, J, 2021) |
| "Forty metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes mellitus, received liraglutide (1." | 9.34 | Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. ( Boccatonda, A; Cipollone, F; Consoli, A; Di Castelnuovo, A; Guagnano, MT; Liani, R; Santilli, F; Simeone, PG; Tripaldi, R; Vadini, F, 2020) |
| " The use of dapagliflozin in this population could improve weight loss and other cardiovascular factors." | 9.34 | Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial. ( Espinosa, E; Ferreira-Hermosillo, A; Garrido-Mendoza, AP; Mendoza-Zubieta, V; Mercado, M; Molina-Ayala, MA; Molina-Guerrero, D; Ramírez-Rentería, C, 2020) |
| " Metformin was able to stabilise insulin sensitivity in every stratified sub-cohort except one." | 9.34 | Metformin use in prediabetes: is earlier intervention better? ( Fleet, R; Pumpa, K; Somerset, S; Warrilow, A, 2020) |
| "To evaluate the effect of metformin therapy on coronary endothelial function and major adverse cardiac events (MACE) in patients with prediabetes with stable angina and nonobstructive coronary stenosis (NOCS)." | 9.30 | Effects of Metformin Therapy on Coronary Endothelial Dysfunction in Patients With Prediabetes With Stable Angina and Nonobstructive Coronary Artery Stenosis: The CODYCE Multicenter Prospective Study. ( Balestrieri, ML; Barbieri, M; Calabrò, P; D'Onofrio, N; Marfella, R; Mauro, C; Minicucci, F; Paolisso, G; Paolisso, P; Portoghese, M; Rizzo, MR; Sacra, C; Sardu, C; Sasso, FC, 2019) |
| "Metformin treatment significantly reduced LVMI, LVM, office systolic BP, body weight, and oxidative stress." | 9.30 | A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. ( Al-Talabany, S; Baig, F; Bhalraam, U; Choy, AM; Gandy, SJ; George, J; Houston, JG; Hussain, MS; Khan, F; Lang, CC; Matthew, S; McKinnie, A; Mohan, M; Mordi, IR; Singh, JSS; Struthers, AD, 2019) |
| " The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves β-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR." | 9.24 | Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. ( Goricar, K; Janez, A; Jensterle, M, 2017) |
| "Sixty-two metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes, were randomized to liraglutide (1." | 9.24 | Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes. ( Angelucci, E; Bonadonna, RC; Cianfarani, S; Consoli, A; Davì, G; Di Castelnuovo, A; Federico, V; Guagnano, MT; Leo, M; Maccarone, MT; Manzoli, L; Santilli, F; Sborgia, C; Simeone, PG; Tartaro, A, 2017) |
| "To evaluate efficacy with the dipeptidyl peptidase-4 inhibitor saxagliptin (SAXA), metformin extended release (MET), and combination (SAXA-MET) in patients with polycystic ovary syndrome (PCOS) and impaired glucose regulation." | 9.24 | Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot ( Elkind-Hirsch, KE; Gutowski, HC; Paterson, MS; Seidemann, EL, 2017) |
| "In individuals with prediabetes, metformin ameliorated effector pathways that have been shown to regulate longevity in animal models." | 9.20 | Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes. A randomized controlled trial. ( Avogaro, A; Bacalini, MG; Borelli, V; Cattelan, A; Ceolotto, G; de Kreutzenberg, SV; Fadini, GP; Franceschi, C; Garagnani, P; Mazzucato, M; Pagnin, E, 2015) |
| "Our study included 41 fenofibrate-treated patients with impaired glucose tolerance allocated to either metformin (3 g daily) or placebo." | 9.17 | Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance. ( Gdula-Dymek, A; Krysiak, R; Okopień, B, 2013) |
| "Physical activity or metformin enhances insulin sensitivity and opposes the progression from prediabetes to type 2 diabetes." | 9.16 | Independent and combined effects of exercise training and metformin on insulin sensitivity in individuals with prediabetes. ( Braun, B; Chipkin, SR; Gerber, R; Malin, SK, 2012) |
| "Metformin produced weight loss and delayed or prevented diabetes in the Diabetes Prevention Program (DPP)." | 9.16 | Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. ( , 2012) |
| "0; 38 females) with abdominal obesity and either impaired fasting glucose, elevated HbA1c, or impaired glucose tolerance (IGT) who were randomized to receive 3-months of exenatide or metformin." | 9.16 | Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. ( Bank, AJ; Bergenstal, RM; Gonzalez-Campoy, JM; Katz, H; Kelly, AS, 2012) |
| "In this multicenter, randomized, double-blind, placebo-controlled, parallel-group trial, drug-naïve patients with type 2 DM will be randomized 1 : 1 to metformin + colesevelam HCl or metformin + matching placebo, while those with prediabetes will be randomized 1 : 1 to colesevelam HCl or placebo, for 16 weeks of treatment." | 9.14 | Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes. ( Abby, SL; Hernandez-Triana, E; Jin, X; Jones, MR; Lai, YL; Misir, S; Mudaliar, S; Nagendran, S; Unnikrishnan, AG, 2009) |
| "Based on the known effect of metformin (MET) in improving insulin sensitivity in type 2 diabetes, with the scope to focus the effects on glycaemic and free fatty acids (FFA) levels, we studied the effects of a short-term treatment with this drug in obese subjects and obese patients with diabetes or family history of diabetes (FHD)." | 9.11 | Effects of short-term metformin treatment on insulin sensitivity of blood glucose and free fatty acids. ( Belfiore, F; Bellomia, D; Camuto, M; Cavaleri, A; Iannello, S; Milazzo, P; Pisano, MG, 2004) |
| "To determine if the use of metformin in people with prediabetes (impaired glucose tolerance or impaired fasting glucose) would prevent or delay the onset of frank type 2 diabetes mellitus." | 8.85 | Treating prediabetes with metformin: systematic review and meta-analysis. ( Godwin, M; Lilly, M; Lily, M, 2009) |
| "To estimate the effectiveness of metformin on glycaemic parameters among participants with incident prediabetes attending Australian general practices." | 8.31 | Do patients with prediabetes managed with metformin achieve better glycaemic control? A national study using primary care medical records. ( Begum, M; Bernardo, CO; Gonzalez-Chica, D; Jahan, H; Stocks, N; Zheng, M, 2023) |
| "Metformin treatment decreases thyrotropin levels in individuals with hypothyroidism and this effect seems to be mediated by the 5'-adenosine monophosphate-activated protein kinase pathway in the pituitary." | 8.12 | Rosuvastatin potentiates the thyrotropin-lowering effect of metformin in men with non-autoimmune subclinical hypothyroidism and prediabetes. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "To use the framework of the Health Belief Model (HBM) to explore factors associated with metformin use among adults with prediabetes." | 8.12 | Health Beliefs Associated With Metformin Use Among Insured Adults With Prediabetes. ( Herman, WH; Hurst, TE; Joiner, KL; McEwen, LN, 2022) |
| "This observational, retrospective study utilized EHR data from 52 hospitals for COVID-19 patients with PCOS or prediabetes treated with metformin or levothyroxine/ondansetron (controls)." | 8.12 | Metformin is associated with reduced COVID-19 severity in patients with prediabetes. ( Antony, B; Blau, H; Bramante, C; Casiraghi, E; Chan, LE; Coleman, B; Gargano, M; Haendel, M; Harris, NL; Laraway, B; Reese, J; Robinson, PN; Sahner, D; Valentini, G; Wilkins, K; Zaman, A, 2022) |
| "This study aimed to investigate the effects of metformin on gingival wound healing in insulin-resistant prediabetes." | 8.12 | Metformin accelerates wound healing by Akt phosphorylation of gingival fibroblasts in insulin-resistant prediabetes mice. ( Buranasin, P; Iwata, T; Kido, D; Kominato, H; Mikami, R; Mizutani, K; Nagasawa, T; Nakagawa, K; Saito, N; Takeda, K; Takemura, S, 2022) |
| " This study was to assess clozapine-induced metformin-resistant prediabetes/diabetes and its correlation with clinical efficacy in schizophrenia E-TR subtype." | 8.02 | Clozapine induces metformin-resistant prediabetes/diabetes that is associated with poor clinical efficacy in patients with early treatment-resistant schizophrenia. ( Chen, J; Chen, Y; Fang, T; Huang, G; Li, B; Li, Q; Lin, C; Liu, J; Ma, X; Shao, H; Tian, H; Wang, H; Xu, S; Xu, Y; Yang, A; Yang, W; Yao, C; Yu, X; Zhou, C; Zhuo, C, 2021) |
| "Metformin treatment in females with prediabetes reduces BMI, waist circumference, fasting blood glucose, and HbA1c." | 8.02 | Effect of Metformin on Anthropometric Measurements and Hormonal and Biochemical Profile in Patients with Prediabetes. ( Ajlouni, K; Batieha, A; El-Khateeb, M; Farahid, O; Hyassat, D; Khader, Y; Safiah, M, 2021) |
| "Metformin reduced prolactin levels only in women with hyperprolactinemia." | 8.02 | The Impact of Ethinyl Estradiol on Metformin Action on Prolactin Levels in Women with Hyperprolactinemia. ( Krysiak, R; Okopień, B; Szkróbka, W, 2021) |
| "The American Diabetes Association (ADA) recommends that treatment with metformin be considered for prevention of type 2 diabetes in persons with prediabetes." | 7.96 | Trends in Self-reported Prediabetes and Metformin Use in the USA: NHANES 2005-2014. ( Foti, K; Grams, ME; Liu, C; Selvin, E; Shin, JI, 2020) |
| " In both groups, metformin reduced glucose levels, homeostasis model assessment 1 of insulin resistance index (HOMA1-IR), thyrotropin levels and Jostel's thyrotropin index, as well as increased SPINA-GT." | 7.96 | The impact of oral hormonal contraception on metformin action on hypothalamic-pituitary-thyroid axis activity in women with diabetes and prediabetes: A pilot study. ( Kowalcze, K; Krysiak, R; Okopień, B; Wolnowska, M, 2020) |
| " Here, we evaluated inflammation and leptin to adiponectin ratio in pericoronary fat from patients subjected to coronary artery bypass grafting (CABG) for acute myocardial infarction (AMI)." | 7.91 | Pericoronary fat inflammation and Major Adverse Cardiac Events (MACE) in prediabetic patients with acute myocardial infarction: effects of metformin. ( Balestrieri, ML; Barbieri, M; D'Onofrio, N; De Feo, M; Galdiero, M; Loreni, F; Marfella, R; Mureddu, S; Paolisso, G; Portoghese, M; Rizzo, MR; Sardu, C; Scisciola, L; Signoriello, G; Torella, M, 2019) |
| "We found no clear evidence of any adverse outcomes related to the use of metformin for the treatment of hyperglycemia in pregnancy." | 7.91 | Real-world experience of metformin use in pregnancy: Observational data from the Northern Territory Diabetes in Pregnancy Clinical Register. ( Barzi, F; Boyle, J; Brown, A; Chitturi, S; Connors, C; Corpus, S; Cotter, M; Dowden, M; Inglis, C; Kirkham, R; Kirkwood, M; Lee, IL; Lindenmayer, G; Longmore, D; Maple-Brown, LJ; McIntyre, HD; Moore, E; O'Dea, K; Oats, J; Shaw, JE; Thomas, S; van Dokkum, P; Whitbread, C; Wicks, M; Zimmet, P, 2019) |
| "Percentage of health plan enrollees with prediabetes who were prescribed metformin." | 7.81 | Metformin prescription for insured adults with prediabetes from 2010 to 2012: a retrospective cohort study. ( Duru, OK; Ettner, S; Ho, S; Keckhafer, A; Li, J; Mangione, CM; Moin, T; Turk, N, 2015) |
| "We investigated whether the addition of metformin to the treatment of overweight and obese individuals further reduces the incidence of type 2 diabetes mellitus (T (2)DM), prediabetes and metabolic syndrome (MetS) and improves cardiovascular disease (CVD) risk factors (RFs)." | 7.75 | The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study. ( Andreadis, EA; Diamantopoulos, EJ; Georgiopoulos, DX; Gouveri, ET; Katsanou, PM; Tsourous, GI; Yfanti, GK, 2009) |
| "Metformin was found to reduce elevated, but not normal, thyrotropin and prolactin levels." | 7.01 | Plasma gonadotropin levels in metformin-treated men with prediabetes: a non-randomized, uncontrolled pilot study. ( Bednarska-Czerwińska, A; Krysiak, R; Okopień, B; Szkróbka, W, 2021) |
| "Treatment with dapagliflozin and interval-based exercise lead to similar but small improvements in glycaemic variability compared with control and metformin therapy." | 7.01 | The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial. ( Amadid, H; Blond, MB; Bruhn, L; Clemmensen, KKB; Dejgaard, TF; Færch, K; Jørgensen, ME; Karstoft, K; Pedersen, C; Persson, F; Ried-Larsen, M; Tvermosegaard, M; Vainø, CTR; Vistisen, D, 2021) |
| "Prediabetes is associated with increased prevalence of cardiovascular disease (CVD)." | 6.87 | Effect of intensive lifestyle modification & metformin on cardiovascular risk in prediabetes: A pilot randomized control trial. ( Bantwal, G; Fathima, S; George, B; Kulkarni, S; Umesh, S; Xavier, D, 2018) |
| "Improving insulin sensitivity is one of many proven favourable effects of metformin." | 6.84 | Protocol for a pilot randomised controlled trial of metformin in pre-diabetes after kidney transplantation: the Transplantation and Diabetes (Transdiab) study. ( Alnasrallah, B; Manley, P; Pilmore, H, 2017) |
| "Earlier development of type 2 diabetes is associated with poorer prognoses, and children lose glycemic control more rapidly than adults." | 6.82 | Considering metformin as a second-line treatment for children and adolescents with prediabetes. ( Halpin, K; Hosey, CM; Yan, Y, 2022) |
| "With the increasing incidence of childhood obesity, clinicians need to understand its comorbidities and their management." | 6.55 | Metformin Use in Children and Adolescents with Prediabetes. ( Chin, VL; Khokhar, A; Perez-Colon, S; Umpaichitra, V, 2017) |
| "Metformin is a widely used drug in the treatment of type 2 diabetes mellitus (T2DM)." | 6.52 | Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease. ( Bettencourt, N; Fontes-Carvalho, R; Gama, V; Ladeiras-Lopes, R; Leite-Moreira, A; Sampaio, F, 2015) |
| "The Diabetes Prevention Program (DPP) and metformin can prevent or delay the onset of type 2 diabetes mellitus (T2DM) among patients with prediabetes." | 5.69 | Study protocol: Behavioral economics and self-determination theory to change diabetes risk (BEST Change). ( Carter, EW; Heisler, M; Herman, WH; Kim, HM; Kullgren, JT; McEwen, LN; Resnicow, K; Rogers, B; Stoll, S; Vadari, HS; Volpp, KG, 2023) |
| " We conducted a Phase II double-blind placebo-controlled trial that aimed to determine the impact of metformin on blood glucose levels among people with prediabetes (defined as impaired fasting glucose [IFG] and/or impaired glucose tolerance [IGT]) and HIV in SSA." | 5.69 | Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial. ( Alam, U; Bates, K; Charles, G; Garrib, A; Jaffar, S; Kivuyo, S; Luo, H; Majaliwa, E; Mfinanga, S; Nyirenda, MJ; Ramaiya, K; Simbauranga, R; van Widenfelt, E; Wang, D, 2023) |
| "To investigate if addition of metformin to standard care (life-style advice) reduces the occurrence of cardiovascular events and death after myocardial infarction (MI) in patients with newly detected prediabetes." | 5.69 | Design and rationale of the myocardial infarction and new treatment with metformin study (MIMET) - Study protocol for a registry-based randomised clinical trial. ( Hagström, E; Hambraeus, K; James, S; Jernberg, T; Lagerqvist, B; Leosdottir, M; Lundman, P; Norhammar, A; Östlund, O; Pernow, J; Ritsinger, V, 2023) |
| " Methods and Results The Diabetes Prevention Program was a randomized controlled trial comparing an intensive lifestyle intervention, metformin, or placebo for prevention of type 2 diabetes among patients with prediabetes." | 5.69 | Coronary Artery Calcium and Cognitive Decline in the Diabetes Prevention Program Outcomes Study. ( Crandall, JP; Dabelea, D; Gadde, KM; Goldberg, RB; Ibebuogu, UN; Luchsinger, JA; Orchard, TJ; Pi-Sunyer, FX; Schlögl, M; Temprosa, M; Watson, KE; Yin, X, 2023) |
| "Metformin users were younger, had higher body mass index, were more likely to have comorbidities, and had higher baseline hemoglobin A1c levels than non-users." | 5.62 | Use of metformin following a population-level intervention to encourage people with pre-diabetes to enroll in the National Diabetes Prevention Program. ( Herman, WH; Hurst, TE; Joiner, KL; McEwen, LN, 2021) |
| "Patients with prediabetes are making choices for diabetes prevention that generally align with recommendations and expected benefits from the published literature." | 5.62 | Choice of Intensive Lifestyle Change and/or Metformin after Shared Decision Making for Diabetes Prevention: Results from the Prediabetes Informed Decisions and Education (PRIDE) Study. ( Castellon-Lopez, Y; Duru, OK; Frosch, DL; Grotts, J; Jeffers, KS; Mangione, CM; Martin, JM; Moin, T; Norris, KC; Tseng, CH; Turk, N, 2021) |
| "Prediabetes was induced by exposing male Sprague Dawley rats (150-180 g) to high-fat high- carbohydrate (HFHC) diet for 20 weeks." | 5.62 | Preventing the onset of diabetes-induced chronic kidney disease during prediabetes: The effects of oleanolic acid on selected markers of chronic kidney disease in a diet-induced prediabetic rat model. ( Gamede, M; Khathi, A; Mabuza, L; Ngubane, P, 2021) |
| "<6." | 5.56 | Metformin Should Not Be Used to Treat Prediabetes. ( Davidson, MB, 2020) |
| "This study aimed to determine the separated and combined effects of metformin and resistance exercise on glycemic control, insulin sensitivity, and insulin-like growth factor 1 (IGF-1) in overweight/obese individuals with prediabetes and type 2 diabetes mellitus." | 5.51 | One Bout of Resistance Training Does Not Enhance Metformin Actions in Prediabetic and Diabetic Individuals. ( Alvarez-Jimenez, L; Mora-Rodriguez, R; Morales-Palomo, F; Moreno-Cabañas, A; Ortega, JF; Ramirez-Jimenez, M, 2022) |
| " We aimed to explore 7% weight reduction rates of mazindol alone or combined with metformin in non-diabetic obese Mexican subjects who had additional risk factors for T2D." | 5.51 | Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects. ( Arguelles-Tello, FA; Barranco-Garduño, LM; Huerta-Cruz, JC; Kammar-García, A; Reyes-García, JG; Rocha-González, HI; Trejo-Jasso, CA, 2022) |
| "To evaluate the impact of concomitant use of probiotic BB-12 in metformin-treated patients with type 2 diabetes or prediabetes on glycemic control, metformin-related gastrointestinal side effects, and treatment compliance." | 5.51 | Metformin with Versus without Concomitant Probiotic Therapy in Newly Diagnosed Patients with Type 2 Diabetes or Prediabetes: A Comparative Analysis in Relation to Glycemic Control, Gastrointestinal Side Effects, and Treatment Compliance. ( Bostan, F; Çekin, AH; Kök, M; Köker, G; Özçelik Köker, G; Şahin, K; Şahintürk, Y; Uyar, S, 2022) |
| "Metformin was found to decrease serum levels of prolactin and thyrotropin." | 5.48 | The Effect of Metformin on Serum Gonadotropin Levels in Postmenopausal Women with Diabetes and Prediabetes: A Pilot Study. ( Krysiak, R; Okopień, B; Szkróbka, W, 2018) |
| "Osteoprotegerin has been shown to be increased in cardiovascular disorders and type 2 diabetes mellitus." | 5.46 | Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes. ( Arslan, MS; Biyikli Gencturk, Z; Cakal, E; Delibasi, T; Karakose, M; Ozbek, M; Ozturk, G; Sahin, M; Tutal, E; Ucan, B, 2017) |
| "To evaluate clinical efficacy of exenatide (EX), metformin (MET), or combination (COM) for prediabetes in PCOS." | 5.41 | Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study. ( Cai, J; Fan, W; Fu, JR; Gao, YN; Liu, W; Ma, JY; Sun, Y; Tao, T; Wang, YY; Xu, Y; Zhang, Y; Zhu, YC, 2021) |
| " placebo (H-HeFT) and 2) if metformin reduces the incidence of death, worsening heart failure, acute myocardial infarction, and stroke vs." | 5.41 | The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr ( Abdulla, J; Barasa, A; Bibby, BM; Bruun, NE; Brønnum-Schou, J; Bøtker, HE; Bøttcher, M; Dodt, K; Eiskjær, H; Gislason, G; Gustafsson, F; Hansen, VB; Hassager, C; Hollingdal, M; Høfsten, DE; Jonczy, B; Knudsen, AS; Kristensen, SL; Køber, L; Larsen, AH; Lomholdt, J; Madsen, JS; Mahboubi, K; Mellemkjær, S; Mikkelsen, KV; Møller, J; Nielsen, G; Nielsen, OW; Nørrelund, H; Poenaru, MP; Poulsen, MK; Raymond, I; Refsgaard, J; Schou, M; Serup-Hansen, K; Sillesen, K; Steffensen, FH; Torp-Petersen, C; Vraa, S; Wiggers, H, 2021) |
| "To assess the effects of dapagliflozin, metformin and exercise treatment on changes in plasma glucagon concentrations in individuals with overweight and HbA1c-defined prediabetes." | 5.41 | No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial. ( Amadid, H; Blond, MB; Bruhn, L; Clemmensen, KKB; Faerch, K; Holst, JJ; Jørgensen, ME; Karstoft, K; Persson, F; Quist, JS; Ried-Larsen, M; Torekov, SS; Vistisen, D; Wewer Albrechtsen, NJ, 2021) |
| "In this PROBE design trial, people who had recent stroke (within 3 months) with pre-diabetes were randomized to either the active arm (n = 13) receiving usual care plus Metformin XR (500 mg daily increased to a total daily dose of 1500 mg) or the control group receiving only usual care (n = 13)." | 5.41 | Feasibility trial of metformin XR in people with pre-diabetes and stroke (MIPPS)-randomised open blinded endpoint controlled trial. ( Borschmann, K; Churilov, L; Donnan, G; Ekinci, EI; Hachem, M; Lau, LH; Price, SAL; Sumithran, P; Tabesh, M; Thijs, V; Zajac, J, 2021) |
| "Forty metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes mellitus, received liraglutide (1." | 5.34 | Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. ( Boccatonda, A; Cipollone, F; Consoli, A; Di Castelnuovo, A; Guagnano, MT; Liani, R; Santilli, F; Simeone, PG; Tripaldi, R; Vadini, F, 2020) |
| "To determine the separated and combined effects of metformin and exercise on insulin sensitivity and free-living glycemic control in overweight individuals with prediabetes/type 2 diabetes (T2DM)." | 5.34 | Exercise improves metformin 72-h glucose control by reducing the frequency of hyperglycemic peaks. ( Mora-Rodríguez, R; Morales-Palomo, F; Moreno-Cabañas, A; Ortega, JF; Ramirez-Jimenez, M, 2020) |
| " The use of dapagliflozin in this population could improve weight loss and other cardiovascular factors." | 5.34 | Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial. ( Espinosa, E; Ferreira-Hermosillo, A; Garrido-Mendoza, AP; Mendoza-Zubieta, V; Mercado, M; Molina-Ayala, MA; Molina-Guerrero, D; Ramírez-Rentería, C, 2020) |
| " While efficacy studies demonstrate that metformin can reduce incident T2D by half among younger, obese adults with prediabetes, its real-world effectiveness are understudied, and its use for T2D prevention in primary care is low." | 5.34 | Design of a cluster-randomized trial of the effectiveness and cost-effectiveness of metformin on prevention of type 2 diabetes among prediabetic Mexican adults (the PRuDENTE initiative of Mexico City). ( Aguilar-Salinas, CA; Balderas, N; Barquera, S; Basu, S; Denova-Gutiérrez, E; Gallardo-Hernández, A; Handley, MA; López-Arellano, O; Moreno-Loaeza, L; Rodríguez, LA; Sánchez-Romero, LM; Schillinger, D; Sepúlveda-Amor, J, 2020) |
| " Metformin was able to stabilise insulin sensitivity in every stratified sub-cohort except one." | 5.34 | Metformin use in prediabetes: is earlier intervention better? ( Fleet, R; Pumpa, K; Somerset, S; Warrilow, A, 2020) |
| ", the Diabetes Prevention Program) and metformin reduce type 2 diabetes risk among patients with prediabetes." | 5.30 | Effectiveness of Shared Decision-making for Diabetes Prevention: 12-Month Results from the Prediabetes Informed Decision and Education (PRIDE) Trial. ( Castellon-Lopez, Y; Chon, JS; Duru, OK; Frosch, DL; Jeffers, KS; Mangione, CM; Martin, JM; Moin, T; Norris, K; Tseng, CH; Turk, N, 2019) |
| "To evaluate the effect of metformin therapy on coronary endothelial function and major adverse cardiac events (MACE) in patients with prediabetes with stable angina and nonobstructive coronary stenosis (NOCS)." | 5.30 | Effects of Metformin Therapy on Coronary Endothelial Dysfunction in Patients With Prediabetes With Stable Angina and Nonobstructive Coronary Artery Stenosis: The CODYCE Multicenter Prospective Study. ( Balestrieri, ML; Barbieri, M; Calabrò, P; D'Onofrio, N; Marfella, R; Mauro, C; Minicucci, F; Paolisso, G; Paolisso, P; Portoghese, M; Rizzo, MR; Sacra, C; Sardu, C; Sasso, FC, 2019) |
| "Metformin treatment significantly reduced LVMI, LVM, office systolic BP, body weight, and oxidative stress." | 5.30 | A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. ( Al-Talabany, S; Baig, F; Bhalraam, U; Choy, AM; Gandy, SJ; George, J; Houston, JG; Hussain, MS; Khan, F; Lang, CC; Matthew, S; McKinnie, A; Mohan, M; Mordi, IR; Singh, JSS; Struthers, AD, 2019) |
| "This three-arm, randomized, controlled study aimed to determine the differences in the effects of general advice (GA) on lifestyle change, intensive lifestyle modification programme (ILMP) and GA + metformin (GA + Met) in reducing the prevalence of full metabolic syndrome (MetS) in subjects with prediabetes; 294 Saudis with prediabetes (fasting glucose 5." | 5.27 | Effects of Different Dietary and Lifestyle Modification Therapies on Metabolic Syndrome in Prediabetic Arab Patients: A 12-Month Longitudinal Study. ( Al-Attas, OS; Al-Daghri, NM; Al-Saleh, Y; Alfawaz, HA; Aljohani, NJ; Alnaami, AM; Alokail, MS; Kumar, S; Wani, K, 2018) |
| "We analyzed data from the Diabetes Prevention Program (DPP) for 2,476 adults in 1996-1999 with prediabetes randomized to receive treatment with lifestyle modification, metformin, or placebo for 2-3 years and followed through 2014 for T2DM and CVD outcomes." | 5.27 | Use of a Metabolic Syndrome Severity ( DeBoer, MD; Filipp, SL; Gurka, MJ, 2018) |
| " The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves β-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR." | 5.24 | Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. ( Goricar, K; Janez, A; Jensterle, M, 2017) |
| "Sixty-two metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes, were randomized to liraglutide (1." | 5.24 | Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes. ( Angelucci, E; Bonadonna, RC; Cianfarani, S; Consoli, A; Davì, G; Di Castelnuovo, A; Federico, V; Guagnano, MT; Leo, M; Maccarone, MT; Manzoli, L; Santilli, F; Sborgia, C; Simeone, PG; Tartaro, A, 2017) |
| "To evaluate efficacy with the dipeptidyl peptidase-4 inhibitor saxagliptin (SAXA), metformin extended release (MET), and combination (SAXA-MET) in patients with polycystic ovary syndrome (PCOS) and impaired glucose regulation." | 5.24 | Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot ( Elkind-Hirsch, KE; Gutowski, HC; Paterson, MS; Seidemann, EL, 2017) |
| "In the first comparative effectiveness trial of diabetes prevention treatments, a 12-month ILI produced significantly greater weight loss than metformin and standard care among Latinas with prediabetes." | 5.24 | PREVENT-DM Comparative Effectiveness Trial of Lifestyle Intervention and Metformin. ( Ackermann, RT; Alos, VA; Ciolino, JD; Foster, GD; Homko, C; O'Brien, MJ; Perez, A; Scanlan, AB; Whitaker, RC, 2017) |
| " One randomized clinical trial (RCT) (TODAY; n = 699 adolescents with obesity; mean age, 14 years) comparing metformin, metformin plus rosiglitazone, and metformin plus lifestyle intervention reported that 2 youths with recently diagnosed diabetes developed kidney impairment (0 vs 1 vs 1, respectively; P > ." | 5.22 | Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force. ( Ali, R; Allison, BA; Baker, C; Jonas, DE; LeBlanc, ES; Middleton, JC; Riley, S; Vander Schaaf, EB; Voisin, CE, 2022) |
| "The effects of a 1year period of intensive lifestyle change aimed at achieving 7% weight loss or metformin 850mg twice daily versus placebo on HDL-C were assessed in 3070 participants with impaired glucose tolerance, and on HDL particle concentration (HDL-P) and size in a subgroup of 1645 individuals." | 5.22 | Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program. ( Bray, G; Goldberg, RB; Horton, E; Kitabchi, A; Krakoff, J; Marcovina, S; Mather, K; Mele, L; Orchard, T; Perreault, L; Temprosa, M; White, N, 2016) |
| "This study tests the effectiveness of expert guidelines for diabetes prevention: lifestyle intervention with addition of metformin, when required, among people with prediabetes." | 5.22 | The Stepwise Approach to Diabetes Prevention: Results From the D-CLIP Randomized Controlled Trial. ( Ali, MK; Anjana, RM; Mohan, V; Narayan, KM; Ranjani, H; Staimez, LR; Weber, MB, 2016) |
| "Diabetes Prevention Program participants in three treatment arms (intensive life style, metformin, placebo) were assessed for diabetes, glucose control, ADM use, and DS, measured using the Beck Depression Inventory (BDI)." | 5.20 | Depressive symptoms, antidepressant medication use, and new onset of diabetes in participants of the diabetes prevention program and the diabetes prevention program outcomes study. ( Barrett-Connor, E; Carnethon, MR; de Groot, M; Horton, ES; Knowler, WC; Ma, Y; Marrero, DG; Price, DW, 2015) |
| "In individuals with prediabetes, metformin ameliorated effector pathways that have been shown to regulate longevity in animal models." | 5.20 | Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes. A randomized controlled trial. ( Avogaro, A; Bacalini, MG; Borelli, V; Cattelan, A; Ceolotto, G; de Kreutzenberg, SV; Fadini, GP; Franceschi, C; Garagnani, P; Mazzucato, M; Pagnin, E, 2015) |
| "Primary outcomes are clamp-derived glucose-stimulated C-peptide secretion and maximal C-peptide response to arginine during hyperglycemia." | 5.19 | Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span. ( , 2014) |
| "Our study included 41 fenofibrate-treated patients with impaired glucose tolerance allocated to either metformin (3 g daily) or placebo." | 5.17 | Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance. ( Gdula-Dymek, A; Krysiak, R; Okopień, B, 2013) |
| "Physical activity or metformin enhances insulin sensitivity and opposes the progression from prediabetes to type 2 diabetes." | 5.16 | Independent and combined effects of exercise training and metformin on insulin sensitivity in individuals with prediabetes. ( Braun, B; Chipkin, SR; Gerber, R; Malin, SK, 2012) |
| "Metformin produced weight loss and delayed or prevented diabetes in the Diabetes Prevention Program (DPP)." | 5.16 | Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. ( , 2012) |
| "0; 38 females) with abdominal obesity and either impaired fasting glucose, elevated HbA1c, or impaired glucose tolerance (IGT) who were randomized to receive 3-months of exenatide or metformin." | 5.16 | Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. ( Bank, AJ; Bergenstal, RM; Gonzalez-Campoy, JM; Katz, H; Kelly, AS, 2012) |
| "The study population included women in premenopause (n = 708), women in natural postmenopause (n = 328), and women with bilateral oophorectomy (n = 201) in the Diabetes Prevention Program, a randomized placebo-controlled trial of lifestyle intervention and metformin among glucose-intolerant adults." | 5.15 | Menopause and risk of diabetes in the Diabetes Prevention Program. ( Barrett-Connor, E; Crandall, JP; Dabelea, D; Edelstein, SL; Foulkes, MA; Hamman, RF; Kim, C; Kitabchi, AE; Montez, MG; Perreault, L, 2011) |
| "In this multicenter, randomized, double-blind, placebo-controlled, parallel-group trial, drug-naïve patients with type 2 DM will be randomized 1 : 1 to metformin + colesevelam HCl or metformin + matching placebo, while those with prediabetes will be randomized 1 : 1 to colesevelam HCl or placebo, for 16 weeks of treatment." | 5.14 | Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes. ( Abby, SL; Hernandez-Triana, E; Jin, X; Jones, MR; Lai, YL; Misir, S; Mudaliar, S; Nagendran, S; Unnikrishnan, AG, 2009) |
| "Based on the known effect of metformin (MET) in improving insulin sensitivity in type 2 diabetes, with the scope to focus the effects on glycaemic and free fatty acids (FFA) levels, we studied the effects of a short-term treatment with this drug in obese subjects and obese patients with diabetes or family history of diabetes (FHD)." | 5.11 | Effects of short-term metformin treatment on insulin sensitivity of blood glucose and free fatty acids. ( Belfiore, F; Bellomia, D; Camuto, M; Cavaleri, A; Iannello, S; Milazzo, P; Pisano, MG, 2004) |
| " Because metformin improves peripheral insulin sensitivity, we examined the acute effect of metformin and placebo on glucose and lipid metabolism in nine insulin-resistant first-degree relatives of NIDDM patients with the euglycemic insulin-clamp technique combined with indirect calorimetry and infusion of [3-3H]glucose." | 5.07 | Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. ( Eriksson, JG; Groop, LC; Widén, EI, 1992) |
| " Metformin and SGLT2 inhibitors should be discontinued in patients with severe forms of COVID-19 owing to the risks of lactic acidosis and ketoacidosis." | 5.05 | COVID-19 in diabetic patients: Related risks and specifics of management. ( Hermans, MP; Maiter, D; Orioli, L; Thissen, JP; Vandeleene, B; Yombi, JC, 2020) |
| "We included randomised controlled trials (RCTs) with a duration of one year or more comparing metformin with any pharmacological glucose-lowering intervention, behaviour-changing intervention, placebo or standard care in people with impaired glucose tolerance, impaired fasting glucose, moderately elevated glycosylated haemoglobin A1c (HbA1c) or combinations of these." | 5.01 | Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. ( Chi, Y; Hemmingsen, B; Madsen, KS; Metzendorf, MI; Richter, B, 2019) |
| "Forty articles met inclusion criteria and were summarized into four general categories: (1) RCTs of metformin use for diabetes prevention (n=7 and n=2 follow-up analyses); (2) observational analyses examining metformin use in heterogeneous subgroups of patients with prediabetes (n=9 from the Diabetes Prevention Program, n=1 from the biguanides and the prevention of the risk of obesity [BIGPRO] trial); (3) observational analyses examining cost effectiveness of metformin use for diabetes prevention (n=11 from the Diabetes Prevention Program, n=1 from the Indian Diabetes Prevention Program); and (4) real-world assessments of metformin eligibility or use for diabetes prevention (n=9)." | 4.98 | Review of Metformin Use for Type 2 Diabetes Prevention. ( Flory, JH; Herman, WH; Karter, AJ; Kruge, LE; Mangione, CM; Moin, T; Schillinger, D; Schmittdiel, JA; Walker, EA; Yeh, J, 2018) |
| " If the patient does not respond with a weight loss of at least 5% and if the HbA1C values are not normalized, pharmacological management should be initiated with a metformin dose of 500 mg / day, increasing up to 1,500 - 1,700 mg / day, according to tolerance." | 4.95 | Prediabetes in Colombia: Expert Consensus. ( Calderón, C; Castillo, J; Escobar, ID; López-Jaramillo, P; Melgarejo, E; Parra, GA, 2017) |
| "Metformin is considered to be the only drug suitable in patients with prediabetes and is the drug of choice in patients with type 2 diabetes." | 4.86 | [Metformin as the first line antidiabetic agent]. ( Svacina, S, 2010) |
| "To determine if the use of metformin in people with prediabetes (impaired glucose tolerance or impaired fasting glucose) would prevent or delay the onset of frank type 2 diabetes mellitus." | 4.85 | Treating prediabetes with metformin: systematic review and meta-analysis. ( Godwin, M; Lilly, M; Lily, M, 2009) |
| "To estimate the effectiveness of metformin on glycaemic parameters among participants with incident prediabetes attending Australian general practices." | 4.31 | Do patients with prediabetes managed with metformin achieve better glycaemic control? A national study using primary care medical records. ( Begum, M; Bernardo, CO; Gonzalez-Chica, D; Jahan, H; Stocks, N; Zheng, M, 2023) |
| "While treatment with metformin or lifestyle modification reduces risk for T2D in patients with prediabetes, neither intervention ultimately offers a mortality benefit." | 4.31 | Should you treat prediabetes? It's complicated. ( Holligan, D; Lyon, C; Radi, R, 2023) |
| "The main aim was to study whether the long-term incidences of type 2 diabetes, pre-diabetes and metabolic syndrome differed between women who were treated with metformin or insulin for gestational diabetes." | 4.12 | Comparison of glucose metabolism and anthropometry in women with previous gestational diabetes treated with metformin vs. insulin: 9-year follow-up of two randomized trials. ( Huhtala, M; Loo, BM; Niinikoski, H; Nikkinen, H; Paavilainen, E; Rönnemaa, T; Tertti, K; Vääräsmäki, M, 2022) |
| "Metformin treatment decreases thyrotropin levels in individuals with hypothyroidism and this effect seems to be mediated by the 5'-adenosine monophosphate-activated protein kinase pathway in the pituitary." | 4.12 | Rosuvastatin potentiates the thyrotropin-lowering effect of metformin in men with non-autoimmune subclinical hypothyroidism and prediabetes. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "To use the framework of the Health Belief Model (HBM) to explore factors associated with metformin use among adults with prediabetes." | 4.12 | Health Beliefs Associated With Metformin Use Among Insured Adults With Prediabetes. ( Herman, WH; Hurst, TE; Joiner, KL; McEwen, LN, 2022) |
| "Among individuals with prediabetes in Saudi Arabia, metformin use was very low despite the evidence supporting its safety, convenience, and efficacy." | 4.12 | The use of metformin for type 2 diabetes prevention: Observational multicenter study from Saudi Arabia. ( Al Yami, MS; Al-Azzeh, O; Alfayez, OM; Aljabri, AF; Almalki, OS; Almohammed, OA; Almutairi, FS; Alsallum, AA, 2022) |
| "This observational, retrospective study utilized EHR data from 52 hospitals for COVID-19 patients with PCOS or prediabetes treated with metformin or levothyroxine/ondansetron (controls)." | 4.12 | Metformin is associated with reduced COVID-19 severity in patients with prediabetes. ( Antony, B; Blau, H; Bramante, C; Casiraghi, E; Chan, LE; Coleman, B; Gargano, M; Haendel, M; Harris, NL; Laraway, B; Reese, J; Robinson, PN; Sahner, D; Valentini, G; Wilkins, K; Zaman, A, 2022) |
| " The moderate hyperglycaemia seen in prediabetes can be treated using a combination of metformin and lifestyle interventions (low-calorie diets and exercising)." | 4.12 | Ameliorative Effects of a Rhenium (V) Compound with Uracil-Derived Ligand Markers Associated with Hyperglycaemia-Induced Renal Dysfunction in Diet-Induced Prediabetic Rats. ( Akinnuga, AM; Booysen, IN; Ismail, MB; Khathi, A; Khumalo, B; Ngubane, P; Sibiya, NH; Siboto, A, 2022) |
| "This study aimed to investigate the effects of metformin on gingival wound healing in insulin-resistant prediabetes." | 4.12 | Metformin accelerates wound healing by Akt phosphorylation of gingival fibroblasts in insulin-resistant prediabetes mice. ( Buranasin, P; Iwata, T; Kido, D; Kominato, H; Mikami, R; Mizutani, K; Nagasawa, T; Nakagawa, K; Saito, N; Takeda, K; Takemura, S, 2022) |
| " This study was to assess clozapine-induced metformin-resistant prediabetes/diabetes and its correlation with clinical efficacy in schizophrenia E-TR subtype." | 4.02 | Clozapine induces metformin-resistant prediabetes/diabetes that is associated with poor clinical efficacy in patients with early treatment-resistant schizophrenia. ( Chen, J; Chen, Y; Fang, T; Huang, G; Li, B; Li, Q; Lin, C; Liu, J; Ma, X; Shao, H; Tian, H; Wang, H; Xu, S; Xu, Y; Yang, A; Yang, W; Yao, C; Yu, X; Zhou, C; Zhuo, C, 2021) |
| "Metformin treatment in females with prediabetes reduces BMI, waist circumference, fasting blood glucose, and HbA1c." | 4.02 | Effect of Metformin on Anthropometric Measurements and Hormonal and Biochemical Profile in Patients with Prediabetes. ( Ajlouni, K; Batieha, A; El-Khateeb, M; Farahid, O; Hyassat, D; Khader, Y; Safiah, M, 2021) |
| " Because of coexistent prediabetes, all individuals received metformin (2." | 4.02 | The impact of metformin on prolactin levels in postmenopausal women. ( Kowalcze, K; Krysiak, R; Okopień, B, 2021) |
| "Sixty-two obese patients in treatment with metformin-with prediabetes (n = 41) or newly diagnosed T2DM (n = 21), were studied." | 4.02 | Insulin resistance and NAFLD may influence memory performance in obese patients with prediabetes or newly-diagnosed type 2 diabetes. ( Ciotti, S; Cipollone, F; Consoli, A; Desideri, G; Di Castelnuovo, A; Guagnano, MT; Liani, R; Santilli, F; Simeone, PG; Tartaro, A; Tripaldi, R; Vadini, F, 2021) |
| "Metformin reduced prolactin levels only in women with hyperprolactinemia." | 4.02 | The Impact of Ethinyl Estradiol on Metformin Action on Prolactin Levels in Women with Hyperprolactinemia. ( Krysiak, R; Okopień, B; Szkróbka, W, 2021) |
| "The American Diabetes Association (ADA) recommends that treatment with metformin be considered for prevention of type 2 diabetes in persons with prediabetes." | 3.96 | Trends in Self-reported Prediabetes and Metformin Use in the USA: NHANES 2005-2014. ( Foti, K; Grams, ME; Liu, C; Selvin, E; Shin, JI, 2020) |
| " In both groups, metformin reduced glucose levels, homeostasis model assessment 1 of insulin resistance index (HOMA1-IR), thyrotropin levels and Jostel's thyrotropin index, as well as increased SPINA-GT." | 3.96 | The impact of oral hormonal contraception on metformin action on hypothalamic-pituitary-thyroid axis activity in women with diabetes and prediabetes: A pilot study. ( Kowalcze, K; Krysiak, R; Okopień, B; Wolnowska, M, 2020) |
| " Here, we evaluated inflammation and leptin to adiponectin ratio in pericoronary fat from patients subjected to coronary artery bypass grafting (CABG) for acute myocardial infarction (AMI)." | 3.91 | Pericoronary fat inflammation and Major Adverse Cardiac Events (MACE) in prediabetic patients with acute myocardial infarction: effects of metformin. ( Balestrieri, ML; Barbieri, M; D'Onofrio, N; De Feo, M; Galdiero, M; Loreni, F; Marfella, R; Mureddu, S; Paolisso, G; Portoghese, M; Rizzo, MR; Sardu, C; Scisciola, L; Signoriello, G; Torella, M, 2019) |
| "We found no clear evidence of any adverse outcomes related to the use of metformin for the treatment of hyperglycemia in pregnancy." | 3.91 | Real-world experience of metformin use in pregnancy: Observational data from the Northern Territory Diabetes in Pregnancy Clinical Register. ( Barzi, F; Boyle, J; Brown, A; Chitturi, S; Connors, C; Corpus, S; Cotter, M; Dowden, M; Inglis, C; Kirkham, R; Kirkwood, M; Lee, IL; Lindenmayer, G; Longmore, D; Maple-Brown, LJ; McIntyre, HD; Moore, E; O'Dea, K; Oats, J; Shaw, JE; Thomas, S; van Dokkum, P; Whitbread, C; Wicks, M; Zimmet, P, 2019) |
| " Among 24 patients found to have prediabetes, PCPs usually (58%) recommended weight loss and increased physical activity but never recommended participation in a Diabetes Prevention Program or use of metformin." | 3.85 | Understanding type 2 diabetes mellitus screening practices among primary care physicians: a qualitative chart-stimulated recall study. ( Cohen, AJ; Hafez, D; Kullgren, JT; Martin, EG; Nelson, DB; Northway, R, 2017) |
| "Metformin treatment is associated with a decreased risk and better prognosis of pancreatic cancer (PC) in patients with type 2 diabetes, but the mechanism of metformin's PC growth inhibition in the context of a prediabetic state is unknown." | 3.81 | Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms. ( Cifarelli, V; Devlin, KL; Dunlap, SM; Huang, J; Hursting, SD; Kaaks, R; Lashinger, LM; Pollak, MN, 2015) |
| "Percentage of health plan enrollees with prediabetes who were prescribed metformin." | 3.81 | Metformin prescription for insured adults with prediabetes from 2010 to 2012: a retrospective cohort study. ( Duru, OK; Ettner, S; Ho, S; Keckhafer, A; Li, J; Mangione, CM; Moin, T; Turk, N, 2015) |
| "OBJECTIVE The Diabetes Prevention Program (DPP) trial investigated rates of progression to diabetes among adults with prediabetes randomized to treatment with placebo, metformin, or intensive lifestyle intervention." | 3.80 | Genetic risk of progression to type 2 diabetes and response to intensive lifestyle or metformin in prediabetic women with and without a history of gestational diabetes mellitus. ( Christophi, CA; Dabelea, D; Dagogo-Jack, S; Florez, JC; Franks, PW; Jablonski, KA; Kim, C; Knowler, WC; Ratner, R; Sullivan, SD, 2014) |
| "We investigated whether the addition of metformin to the treatment of overweight and obese individuals further reduces the incidence of type 2 diabetes mellitus (T (2)DM), prediabetes and metabolic syndrome (MetS) and improves cardiovascular disease (CVD) risk factors (RFs)." | 3.75 | The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study. ( Andreadis, EA; Diamantopoulos, EJ; Georgiopoulos, DX; Gouveri, ET; Katsanou, PM; Tsourous, GI; Yfanti, GK, 2009) |
| "Prominent weight gain (mostly subcutaneous fat area) was observed in the pioglitazone-treated OLETF (O-P) rats versus significant weight loss was observed in the metformin-treated OLETF (O-M) rats." | 3.74 | The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats. ( Ahn, CW; Cha, BS; Choi, SH; Kim, DJ; Kim, SK; Lee, HC; Lee, YJ; Lim, SK; Zhao, ZS, 2007) |
| " A higher proportion of participants in the metformin plus lifestyle intervention group reported adverse events than in the lifestyle intervention alone group, primarily due to more gastrointestinal adverse events." | 3.30 | Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled t ( Bai, J; Cheng, W; Dong, L; Du, J; Fang, H; Gong, Q; Hou, F; Ji, L; Kuang, H; Li, G; Li, Q; Li, Y; Lian, X; Liu, Y; Lu, Q; Qi, L; Ren, W; Shen, S; Sun, N; Wang, X; Wang, Y; Wu, D; Yan, S; Yang, Z; Zhang, L; Zhang, Y, 2023) |
| "Cognizant of the burden of type 1 diabetes, the recommendations also highlight the importance of research to advance our understanding of the etiology of and opportunities for prevention of type 1 diabetes." | 3.01 | The National Clinical Care Commission Report to Congress: Leveraging Federal Policies and Programs to Prevent Diabetes in People With Prediabetes. ( Boltri, JM; Fukagawa, N; Herman, WH; Idzik, S; Leake, E; Powell, C; Schumacher, P; Shell, D; Strogatz, D; Tracer, H; Wu, S, 2023) |
| "Prediabetes is defined by a fasting glucose level of 100 to 125 mg/dL, a glucose level of 140 to 199 mg/dL measured 2 hours after a 75-g oral glucose load, or glycated hemoglobin level (HbA1C) of 5." | 3.01 | Diagnosis and Management of Prediabetes: A Review. ( Dagogo-Jack, S; Echouffo-Tcheugui, JB; Ji, L; Perreault, L, 2023) |
| "Metformin was found to reduce elevated, but not normal, thyrotropin and prolactin levels." | 3.01 | Plasma gonadotropin levels in metformin-treated men with prediabetes: a non-randomized, uncontrolled pilot study. ( Bednarska-Czerwińska, A; Krysiak, R; Okopień, B; Szkróbka, W, 2021) |
| "Treatment with dapagliflozin and interval-based exercise lead to similar but small improvements in glycaemic variability compared with control and metformin therapy." | 3.01 | The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial. ( Amadid, H; Blond, MB; Bruhn, L; Clemmensen, KKB; Dejgaard, TF; Færch, K; Jørgensen, ME; Karstoft, K; Pedersen, C; Persson, F; Ried-Larsen, M; Tvermosegaard, M; Vainø, CTR; Vistisen, D, 2021) |
| " The metformin group will begin dosing at 250 mg/day, increasing to a maximum of 1,000 mg/day." | 2.90 | Hospital-Based Korean Diabetes Prevention Study: A Prospective, Multi-Center, Randomized, Open-Label Controlled Study. ( Ahn, KJ; Chon, S; Rhee, SY; Woo, JT, 2019) |
| "Metformin with TLC treatment effected a therapeutic decrement of the oxidative stress (-15." | 2.87 | Effect of metformin combined with lifestyle modification versus lifestyle modification alone on proinflammatory-oxidative status in drug-naïve pre-diabetic and diabetic patients: A randomized controlled study. ( AbuRuz, S; Al-Athami, T; Bulatova, N; Kasabri, V; Momani, M; Qotineh, A; Yousef, AM; Zayed, A, 2018) |
| "Progression to type 2 diabetes in people at high risk of diabetes can be markedly reduced with interventions designed to correct underlying pathophysiological disturbances (ie, impaired insulin secretion and resistance) in a real-world setting." | 2.87 | Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES). ( Abdul-Ghani, M; Armato, JP; DeFronzo, RA; Ruby, RJ, 2018) |
| "Prediabetes is associated with increased prevalence of cardiovascular disease (CVD)." | 2.87 | Effect of intensive lifestyle modification & metformin on cardiovascular risk in prediabetes: A pilot randomized control trial. ( Bantwal, G; Fathima, S; George, B; Kulkarni, S; Umesh, S; Xavier, D, 2018) |
| "Improving insulin sensitivity is one of many proven favourable effects of metformin." | 2.84 | Protocol for a pilot randomised controlled trial of metformin in pre-diabetes after kidney transplantation: the Transplantation and Diabetes (Transdiab) study. ( Alnasrallah, B; Manley, P; Pilmore, H, 2017) |
| "Earlier development of type 2 diabetes is associated with poorer prognoses, and children lose glycemic control more rapidly than adults." | 2.82 | Considering metformin as a second-line treatment for children and adolescents with prediabetes. ( Halpin, K; Hosey, CM; Yan, Y, 2022) |
| "Normoglycaemia, prediabetes and type 2 diabetes appear to be part of a continuum of increased risk of adverse outcomes." | 2.82 | Vascular complications in prediabetes and type 2 diabetes: a continuous process arising from a common pathology. ( Gottwald-Hostalek, U; Gwilt, M, 2022) |
| "The METFORMIN study is a multi-centre prospective study that consists of two 18-month phases: a double-blind randomized placebo-controlled trial (part 1) and an open-label follow-up study (part 2)." | 2.79 | METFORMIN: an efficacy, safety and pharmacokinetic study on the short-term and long-term use in obese children and adolescents - study protocol of a randomized controlled study. ( Elst, MA; Knibbe, CA; van der Aa, MP; van der Vorst, MM; van Mil, EG, 2014) |
| "When treated with metformin and an exercise program, a structured, reduced energy diet, which is either high-carbohydrate or moderate-carbohydrate with increased-protein, can achieve clinically significant improvements in obese adolescents at risk of type 2 diabetes." | 2.79 | Improved insulin sensitivity and body composition, irrespective of macronutrient intake, after a 12 month intervention in adolescents with pre-diabetes; RESIST a randomised control trial. ( Ambler, GR; Baur, LA; Briody, J; Broderick, CR; Chisholm, K; Cowell, CT; De, S; Garnett, SP; Gow, M; Ho, M; Noakes, M; Srinivasan, S; Steinbeck, K; Woodhead, HJ, 2014) |
| "Metformin treatment reduced plasma levels/activity of the assessed haemostatic risk factors, and this effect correlated with the improvement in insulin sensitivity." | 2.77 | Haemostatic effects of metformin in simvastatin-treated volunteers with impaired fasting glucose. ( Krysiak, R; Okopien, B, 2012) |
| "Obesity has health consequences going beyond glucose elevation." | 2.72 | Pharmacotherapeutic options for prediabetes. ( Rendell, M, 2021) |
| "A key feature in the etiology of type 2 diabetes mellitus, which appears in the prediabetic phase, is a significant deficiency, compared to healthy controls, in highly flexible poly-cis-unsaturated fatty acyl chains in membrane phospholipids." | 2.66 | The Metformin Paradox. ( Bekedam, DJ; Weijers, RNM, 2020) |
| "Prediabetes affects approximately 40% of American adults." | 2.58 | Prevention and Treatment of Type 2 Diabetes: A Pathophysiological-Based Approach. ( Debs, S; Greenfield, JR; Samocha-Bonet, D, 2018) |
| "Metformin treatment for diabetes prevention was estimated to be cost-saving." | 2.55 | Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. ( Aroda, VR; Crandall, JP; Darwin, C; Edelstein, SL; Heckman-Stoddard, BM; Jeffries, SL; Kahn, SE; Knowler, WC; Molitch, ME; Nathan, DM; Perreault, L; Pi-Sunyer, X; Temprosa, M, 2017) |
| "With the increasing incidence of childhood obesity, clinicians need to understand its comorbidities and their management." | 2.55 | Metformin Use in Children and Adolescents with Prediabetes. ( Chin, VL; Khokhar, A; Perez-Colon, S; Umpaichitra, V, 2017) |
| "Metformin is a widely used drug in the treatment of type 2 diabetes mellitus (T2DM)." | 2.52 | Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease. ( Bettencourt, N; Fontes-Carvalho, R; Gama, V; Ladeiras-Lopes, R; Leite-Moreira, A; Sampaio, F, 2015) |
| "Metabolic syndrome is a cluster of conditions that synergistically increase the risk of cardiovascular disease, type 2 diabetes, and premature mortality." | 2.52 | Metabolic Syndrome: Insulin Resistance and Prediabetes. ( Mayans, L, 2015) |
| "The different types of cancer, heterogeneity of populations and presence of comorbidity make it difficult to determine the benefits of metformin in cancer prevention and treatment." | 2.52 | Metformin: risk-benefit profile with a focus on cancer. ( Cazzaniga, M; DeCensi, A; Dunn, BK; Gorlero, F; Lazzeroni, M; Provinciali, N, 2015) |
| "The incidence of type 2 diabetes mellitus (T2DM) has risen to epidemic proportions, and this is associated with enormous cost." | 2.50 | What are the pharmacotherapy options for treating prediabetes? ( Abdul-Ghani, M; Daniele, G; DeFronzo, RA, 2014) |
| "Interventions preventing progression to type 2 diabetes should therefore delay or prevent β-cell failure." | 2.49 | Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. ( Bergman, M, 2013) |
| "Over 2." | 2.48 | Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program. ( Goldberg, RB; Mather, K, 2012) |
| "The progression from prediabetes to type 2 diabetes occurs over many years, strong evidence to support intervention to delay the progression from prediabetes to diabetes." | 2.44 | Approach to the patient with prediabetes. ( Aroda, VR; Ratner, R, 2008) |
| " Acarbose has a very good safety profile and, owing to its straightforward, non-systemic mode of action, avoids most adverse events." | 2.44 | Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. ( Hanefeld, M, 2007) |
| "Type 2 diabetes is a progressive syndrome that evolves toward complete insulin deficiency during the patient's life." | 2.44 | Treatment of type 2 diabetes with combined therapy: what are the pros and cons? ( Massi-Benedetti, M; Orsini-Federici, M, 2008) |
| "Overt type 2 diabetes is usually preceded by a condition known as prediabetes, which is characterized by impaired fasting glucose (IFG) and impaired glucose tolerance (IGT)." | 2.44 | Identification and treatment of prediabetes to prevent progression to type 2 diabetes. ( Fonseca, VA, 2007) |
| "Prediabetes is important to recognise because of at least 2 major implications: increased risk for future diabetes and for atherosclerotic cardiovascular diseases." | 2.43 | Drug therapy in prediabetes. ( Chowdhury, S; Mukhopadhyay, P, 2005) |
| "Except for the outcome incidence of type 2 diabetes in acarbose versus no treatment (two studies), meta-analyses were not possible." | 2.43 | Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. ( Akkermans, RP; De Grauw, WJ; Lucassen, PL; Van de Laar, FA; Van de Lisdonk, EH, 2006) |
| "In these populations, NIDDM may be present in 10% to as much as 50% of the adult population." | 2.40 | [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations]. ( Flórez, H, 1997) |
| "Metformin was started and increased to 1,000 mg twice daily." | 1.91 | Weekly Growth Hormone (Lonapegsomatropin) Causes Severe Transient Hyperglycemia in a Child with Obesity. ( Alkhatib, EH; Dauber, A; Estrada, DE; Majidi, S, 2023) |
| "Metformin, a frontline therapy for type 2 diabetes and related metabolic diseases, results in variable outcomes." | 1.91 | Non-Nutritive Sweetened Beverages Impair Therapeutic Benefits of Metformin in Prediabetic Diet-Induced Obese Mice. ( Bernier, A; de Lartigue, G; Rourk, K; Singh, A, 2023) |
| "Metformin (25 μmol/L) was introduced after initial 12 h with palmitate." | 1.91 | Metformin restores prohormone processing enzymes and normalizes aberrations in secretion of proinsulin and insulin in palmitate-exposed human islets. ( Aydin, B; Bergsten, P; Chowdhury, AI; Forslund, A; Shekha, M; Stenlid, R; Wen, Q, 2023) |
| "Prediabetes was not considered a negative label, but an opportunity, when coupled with a primary care nurse-delivered dietary intervention." | 1.72 | A diagnosis of prediabetes when combined with lifestyle advice and support is considered helpful rather than a negative label by a demographically diverse group: A qualitative study. ( Abel, S; Coppell, KJ; Spedding, T; Tangiora, A; Tipene-Leach, D; Whitehead, LC, 2022) |
| "Recent research has demonstrated that Type 2 Diabetes (T2D) risk is influenced by a number of common polymorphisms, including MC4R rs17782313, PPARG rs1801282, and TCF7L2 rs7903146." | 1.72 | Association of gene polymorphisms with body weight changes in prediabetic patients. ( Ahmetov, II; Egorova, ES; Khasanova, KB; Kiseleva, TA; Medvedeva, MS; Pickering, C; Valeeva, EV; Valeeva, FV, 2022) |
| "Prediabetes, the precursor of type 2 diabetes (T2D), is on the rise in the US, but the determinants of its progression are poorly characterized in youth." | 1.72 | Prediabetes: Adherence to Nutrition Visits Decreases HbA1c in Children and Adolescents. ( Jasmin, G; Lee, AF; Nwosu, BU; Parajuli, S; Sirak, H, 2022) |
| "This early screening, detection, and treatment of prediabetes should be made a national priority." | 1.72 | An Expert Group Consensus Statement on "Approach and Management of Prediabetes in India". ( Baruah, MP; Das, AK; Das, S; Jacob, J; Kalra, S; Kesavadav, J; Mithal, A; Mohan, V; Ramachandran, A; Sahay, R; Sheikh, S; Tiwaskar, M, 2022) |
| "Metformin is a biguanide that exhibits antidiabetic, anticarcinogenic, and anti-inflammatory properties." | 1.72 | High Throughput Study for Molecular Mechanism of Metformin Pre-Diabetic Protection via Microarray Approach. ( Al Shhab, MA; Alrawashdeh, AY; Zihlif, MA, 2022) |
| "Metformin users were younger, had higher body mass index, were more likely to have comorbidities, and had higher baseline hemoglobin A1c levels than non-users." | 1.62 | Use of metformin following a population-level intervention to encourage people with pre-diabetes to enroll in the National Diabetes Prevention Program. ( Herman, WH; Hurst, TE; Joiner, KL; McEwen, LN, 2021) |
| "GI symptoms are common in youth with type 2 diabetes taking metformin XR and SR." | 1.62 | Metformin treatment and gastrointestinal symptoms in youth: Findings from a large tertiary care referral center. ( Chung, ST; Cogen, F; Cravalho, CKL; Hudson, J; Matta, ST; Meyers, AG; Villalobos-Perez, A, 2021) |
| "Prediabetes is a high-risk condition for type 2 diabetes (T2D)." | 1.62 | Metformin Preserves β-Cell Compensation in Insulin Secretion and Mass Expansion in Prediabetic Nile Rats. ( Chan, CB; Huang, H; Lorenz, BR; Zelmanovitz, PH, 2021) |
| "To characterize treatment of prediabetes in primary care." | 1.62 | Treatment of Patients with Prediabetes in a Primary Care Setting 2011-2018: an Observational Study. ( Hu, B; Misra-Hebert, AD; Rastogi, R; Rothberg, MB; Speaker, SL; Sussman, TA, 2021) |
| "Metformin's NMB was negative for the lowest population risk quintile." | 1.62 | Targeting of the diabetes prevention program leads to substantial benefits when capacity is constrained. ( Cohen, JT; Kent, DM; Olchanski, N; Ruthazer, R; van Klaveren, D; Wong, JB, 2021) |
| "Patients with prediabetes are making choices for diabetes prevention that generally align with recommendations and expected benefits from the published literature." | 1.62 | Choice of Intensive Lifestyle Change and/or Metformin after Shared Decision Making for Diabetes Prevention: Results from the Prediabetes Informed Decisions and Education (PRIDE) Study. ( Castellon-Lopez, Y; Duru, OK; Frosch, DL; Grotts, J; Jeffers, KS; Mangione, CM; Martin, JM; Moin, T; Norris, KC; Tseng, CH; Turk, N, 2021) |
| "Prediabetes was induced by exposing male Sprague Dawley rats (150-180 g) to high-fat high- carbohydrate (HFHC) diet for 20 weeks." | 1.62 | Preventing the onset of diabetes-induced chronic kidney disease during prediabetes: The effects of oleanolic acid on selected markers of chronic kidney disease in a diet-induced prediabetic rat model. ( Gamede, M; Khathi, A; Mabuza, L; Ngubane, P, 2021) |
| "Treatment with metformin reduced peripheral metabolic impairment and cardiac dysfunction via decreased cardiac mitochondrial dysfunction, mitochondrial dynamic imbalance, and apoptosis." | 1.62 | Necrostatin-1 reduces cardiac and mitochondrial dysfunction in prediabetic rats. ( Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Jinawong, K; Kerdphoo, S; Singhanat, K, 2021) |
| "<6." | 1.56 | Metformin Should Not Be Used to Treat Prediabetes. ( Davidson, MB, 2020) |
| "To examine the incidence of type 2 diabetes in people with newly diagnosed prediabetes and the factors that protect against this progression." | 1.51 | What protects against pre-diabetes progressing to diabetes? Observational study of integrated health and social data. ( Blakely, T; Jansen, R; Krebs, J; Masters-Awatere, B; Oetzel, J; Scott, N; Teng, A, 2019) |
| "Metformin was found to decrease serum levels of prolactin and thyrotropin." | 1.48 | The Effect of Metformin on Serum Gonadotropin Levels in Postmenopausal Women with Diabetes and Prediabetes: A Pilot Study. ( Krysiak, R; Okopień, B; Szkróbka, W, 2018) |
| "Osteoprotegerin has been shown to be increased in cardiovascular disorders and type 2 diabetes mellitus." | 1.46 | Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes. ( Arslan, MS; Biyikli Gencturk, Z; Cakal, E; Delibasi, T; Karakose, M; Ozbek, M; Ozturk, G; Sahin, M; Tutal, E; Ucan, B, 2017) |
| "Detection and treatment of prediabetes is an effective strategy in diabetes prevention." | 1.43 | Prediabetes Screening and Treatment in Diabetes Prevention: The Impact of Physician Attitudes. ( Carek, PJ; Mainous, AG; Porter, M; Scuderi, CB; Tanner, RJ, 2016) |
| "About 350 million people worldwide have type 2 diabetes (T2D)." | 1.42 | Increased Plasma Levels of Xanthurenic and Kynurenic Acids in Type 2 Diabetes. ( Oxenkrug, GF, 2015) |
| "The growing epidemic of type 2 diabetes is one of the leading causes of premature morbidity and mortality worldwide, mainly due to the micro- and macrovascular complications associated with the disease." | 1.39 | The early treatment of type 2 diabetes. ( Pratley, RE, 2013) |
| "Overt type 2 diabetes is usually preceded by a condition known as prediabetes, which is characterized by impaired fasting glucose (IFG) and impaired glucose tolerance (IGT)." | 1.35 | Identification and treatment of prediabetes to prevent progression to type 2 diabetes. ( Fonseca, VA, 2008) |
| "Impaired glucose tolerance is defined as two-hour glucose levels of 140 to 199 mg per dL (7." | 1.32 | Impaired glucose tolerance and impaired fasting glucose. ( Disraeli, P; McGregor, T; Rao, SS, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (1.32) | 18.2507 |
| 2000's | 22 (9.65) | 29.6817 |
| 2010's | 107 (46.93) | 24.3611 |
| 2020's | 96 (42.11) | 2.80 |
| Authors | Studies |
|---|---|
| Zhuo, C | 1 |
| Xu, Y | 2 |
| Wang, H | 1 |
| Zhou, C | 1 |
| Liu, J | 1 |
| Yu, X | 1 |
| Shao, H | 1 |
| Tian, H | 1 |
| Fang, T | 1 |
| Li, Q | 3 |
| Chen, J | 1 |
| Xu, S | 1 |
| Ma, X | 1 |
| Yang, W | 1 |
| Yao, C | 1 |
| Li, B | 1 |
| Yang, A | 1 |
| Chen, Y | 1 |
| Huang, G | 1 |
| Lin, C | 1 |
| Hurst, TE | 2 |
| McEwen, LN | 5 |
| Joiner, KL | 2 |
| Herman, WH | 8 |
| Oo, TT | 1 |
| Sumneang, N | 1 |
| Ongnok, B | 1 |
| Arunsak, B | 2 |
| Chunchai, T | 2 |
| Kerdphoo, S | 2 |
| Apaijai, N | 3 |
| Pratchayasakul, W | 3 |
| Liang, G | 1 |
| Chattipakorn, N | 4 |
| Chattipakorn, SC | 4 |
| Safiah, M | 1 |
| Hyassat, D | 1 |
| Khader, Y | 1 |
| Farahid, O | 1 |
| Batieha, A | 1 |
| El-Khateeb, M | 1 |
| Ajlouni, K | 1 |
| Coppell, KJ | 1 |
| Abel, S | 1 |
| Whitehead, LC | 1 |
| Tangiora, A | 1 |
| Spedding, T | 1 |
| Tipene-Leach, D | 1 |
| Tracer, H | 2 |
| Mohnot, S | 1 |
| Moreno-Cabañas, A | 3 |
| Ortega, JF | 3 |
| Morales-Palomo, F | 3 |
| Ramirez-Jimenez, M | 2 |
| Alvarez-Jimenez, L | 2 |
| Mora-Rodriguez, R | 3 |
| Tseng, E | 1 |
| Durkin, N | 1 |
| Clark, JM | 2 |
| Maruthur, NM | 2 |
| Marsteller, JA | 1 |
| Segal, JB | 1 |
| Huhtala, M | 1 |
| Nikkinen, H | 1 |
| Paavilainen, E | 1 |
| Niinikoski, H | 1 |
| Vääräsmäki, M | 1 |
| Loo, BM | 1 |
| Rönnemaa, T | 1 |
| Tertti, K | 1 |
| Valeeva, FV | 1 |
| Medvedeva, MS | 1 |
| Khasanova, KB | 1 |
| Valeeva, EV | 1 |
| Kiseleva, TA | 1 |
| Egorova, ES | 1 |
| Pickering, C | 1 |
| Ahmetov, II | 1 |
| Hosey, CM | 1 |
| Halpin, K | 1 |
| Yan, Y | 1 |
| Arguelles-Tello, FA | 1 |
| Kammar-García, A | 1 |
| Trejo-Jasso, CA | 1 |
| Huerta-Cruz, JC | 1 |
| Barranco-Garduño, LM | 1 |
| Rocha-González, HI | 1 |
| Reyes-García, JG | 1 |
| Parajuli, S | 1 |
| Jasmin, G | 1 |
| Sirak, H | 1 |
| Lee, AF | 1 |
| Nwosu, BU | 1 |
| Gottwald-Hostalek, U | 1 |
| Gwilt, M | 2 |
| Mooranian, A | 1 |
| Chester, J | 1 |
| Johnston, E | 1 |
| Ionescu, CM | 1 |
| Walker, D | 1 |
| Jones, M | 1 |
| Wagle, SR | 1 |
| Kovacevic, B | 1 |
| Foster, T | 1 |
| Mikov, M | 1 |
| Al-Salami, H | 1 |
| Krysiak, R | 10 |
| Kowalcze, K | 3 |
| Okopień, B | 10 |
| Şahin, K | 1 |
| Şahintürk, Y | 1 |
| Köker, G | 1 |
| Özçelik Köker, G | 1 |
| Bostan, F | 1 |
| Kök, M | 1 |
| Uyar, S | 1 |
| Çekin, AH | 1 |
| Jonas, DE | 1 |
| Vander Schaaf, EB | 1 |
| Riley, S | 1 |
| Allison, BA | 1 |
| Middleton, JC | 1 |
| Baker, C | 1 |
| Ali, R | 1 |
| Voisin, CE | 1 |
| LeBlanc, ES | 1 |
| Alfayez, OM | 1 |
| Alsallum, AA | 1 |
| Aljabri, AF | 1 |
| Almutairi, FS | 1 |
| Al-Azzeh, O | 1 |
| Almalki, OS | 1 |
| Al Yami, MS | 1 |
| Almohammed, OA | 1 |
| Yeung, KF | 1 |
| Lee, YQ | 1 |
| Chong, MFF | 1 |
| Gandhi, M | 1 |
| Lam, AYR | 1 |
| Julianty, S | 1 |
| Tan, GCS | 1 |
| Ho, ETL | 1 |
| Goh, SY | 1 |
| Tan, GSW | 1 |
| Shum, EJW | 1 |
| Finkelstein, EA | 1 |
| Jafar, TH | 1 |
| van Dam, RM | 1 |
| Teoh, YL | 1 |
| Thumboo, J | 1 |
| Bee, YM | 1 |
| Chiou, TT | 1 |
| Ge, Y | 1 |
| Romley, JA | 1 |
| Chan, LE | 3 |
| Casiraghi, E | 3 |
| Laraway, B | 3 |
| Coleman, B | 3 |
| Blau, H | 3 |
| Zaman, A | 3 |
| Harris, NL | 3 |
| Wilkins, K | 3 |
| Antony, B | 3 |
| Gargano, M | 3 |
| Valentini, G | 3 |
| Sahner, D | 3 |
| Haendel, M | 3 |
| Robinson, PN | 3 |
| Bramante, C | 3 |
| Reese, J | 3 |
| Carter, EW | 3 |
| Vadari, HS | 3 |
| Stoll, S | 3 |
| Rogers, B | 3 |
| Resnicow, K | 3 |
| Heisler, M | 3 |
| Kim, HM | 3 |
| Volpp, KG | 3 |
| Kullgren, JT | 4 |
| Flowers, E | 2 |
| Aouizerat, BE | 2 |
| Kanaya, AM | 2 |
| Florez, JC | 6 |
| Gong, X | 2 |
| Zhang, L | 4 |
| Siboto, A | 2 |
| Akinnuga, AM | 2 |
| Khumalo, B | 2 |
| Ismail, MB | 2 |
| Booysen, IN | 2 |
| Sibiya, NH | 2 |
| Ngubane, P | 3 |
| Khathi, A | 4 |
| Li, JH | 2 |
| Perry, JA | 2 |
| Jablonski, KA | 4 |
| Srinivasan, S | 4 |
| Chen, L | 3 |
| Todd, JN | 2 |
| Harden, M | 3 |
| Mercader, JM | 3 |
| Pan, Q | 3 |
| Dawed, AY | 2 |
| Yee, SW | 2 |
| Pearson, ER | 2 |
| Giacomini, KM | 2 |
| Giri, A | 2 |
| Hung, AM | 2 |
| Xiao, S | 2 |
| Williams, LK | 2 |
| Franks, PW | 5 |
| Hanson, RL | 2 |
| Kahn, SE | 7 |
| Knowler, WC | 8 |
| Pollin, TI | 2 |
| Boltri, JM | 1 |
| Strogatz, D | 1 |
| Idzik, S | 1 |
| Schumacher, P | 1 |
| Fukagawa, N | 1 |
| Leake, E | 1 |
| Powell, C | 1 |
| Shell, D | 1 |
| Wu, S | 1 |
| Cunningham, A | 1 |
| Li, E | 1 |
| Silverio, A | 1 |
| Mills, G | 1 |
| Han, J | 1 |
| Waters, A | 1 |
| Alkhatib, EH | 1 |
| Dauber, A | 1 |
| Estrada, DE | 1 |
| Majidi, S | 1 |
| Echouffo-Tcheugui, JB | 1 |
| Perreault, L | 6 |
| Ji, L | 3 |
| Dagogo-Jack, S | 3 |
| Singh, A | 1 |
| Rourk, K | 1 |
| Bernier, A | 1 |
| de Lartigue, G | 1 |
| Das, AK | 1 |
| Mohan, V | 2 |
| Ramachandran, A | 3 |
| Kalra, S | 2 |
| Mithal, A | 1 |
| Sahay, R | 1 |
| Tiwaskar, M | 1 |
| Das, S | 2 |
| Baruah, MP | 1 |
| Jacob, J | 1 |
| Sheikh, S | 1 |
| Kesavadav, J | 1 |
| Zheng, M | 1 |
| Begum, M | 1 |
| Bernardo, CO | 1 |
| Stocks, N | 1 |
| Jahan, H | 1 |
| Gonzalez-Chica, D | 1 |
| Zhang, Y | 3 |
| Shen, S | 2 |
| Wang, X | 2 |
| Dong, L | 2 |
| Ren, W | 2 |
| Li, Y | 2 |
| Bai, J | 1 |
| Gong, Q | 1 |
| Kuang, H | 2 |
| Qi, L | 2 |
| Lu, Q | 1 |
| Cheng, W | 2 |
| Liu, Y | 2 |
| Yan, S | 2 |
| Wu, D | 1 |
| Fang, H | 1 |
| Hou, F | 1 |
| Wang, Y | 1 |
| Yang, Z | 1 |
| Lian, X | 1 |
| Du, J | 1 |
| Sun, N | 2 |
| Li, G | 2 |
| Garrib, A | 1 |
| Kivuyo, S | 1 |
| Bates, K | 1 |
| Ramaiya, K | 1 |
| Wang, D | 1 |
| Majaliwa, E | 1 |
| Simbauranga, R | 1 |
| Charles, G | 1 |
| van Widenfelt, E | 1 |
| Luo, H | 2 |
| Alam, U | 1 |
| Nyirenda, MJ | 1 |
| Jaffar, S | 1 |
| Mfinanga, S | 1 |
| Mora-Gonzalez, D | 1 |
| Ritsinger, V | 1 |
| Hagström, E | 1 |
| Hambraeus, K | 1 |
| James, S | 1 |
| Jernberg, T | 1 |
| Lagerqvist, B | 1 |
| Leosdottir, M | 1 |
| Lundman, P | 1 |
| Pernow, J | 1 |
| Östlund, O | 1 |
| Norhammar, A | 1 |
| Wen, Q | 1 |
| Chowdhury, AI | 1 |
| Aydin, B | 1 |
| Shekha, M | 1 |
| Stenlid, R | 1 |
| Forslund, A | 1 |
| Bergsten, P | 1 |
| Holligan, D | 1 |
| Radi, R | 1 |
| Lyon, C | 1 |
| Duru, OK | 5 |
| Mangione, CM | 6 |
| Turk, N | 4 |
| Chon, J | 1 |
| Fu, J | 1 |
| Cheng, G | 1 |
| Cheng, F | 1 |
| Moss, A | 1 |
| Frosch, D | 1 |
| Jeffers, KS | 3 |
| Castellon-Lopez, Y | 3 |
| Tseng, CH | 3 |
| Maranon, R | 1 |
| Norris, KC | 2 |
| Moin, T | 7 |
| Gadde, KM | 1 |
| Yin, X | 1 |
| Goldberg, RB | 3 |
| Orchard, TJ | 1 |
| Schlögl, M | 1 |
| Dabelea, D | 4 |
| Ibebuogu, UN | 2 |
| Watson, KE | 1 |
| Pi-Sunyer, FX | 1 |
| Crandall, JP | 3 |
| Temprosa, M | 3 |
| Luchsinger, JA | 1 |
| Elkhatib, MAW | 1 |
| Mroueh, A | 1 |
| Rafeh, RW | 1 |
| Sleiman, F | 1 |
| Fouad, H | 1 |
| Saad, EI | 1 |
| Fouda, MA | 1 |
| Elgaddar, O | 1 |
| Issa, K | 1 |
| Eid, AH | 1 |
| Eid, AA | 1 |
| Abd-Elrahman, KS | 1 |
| El-Yazbi, AF | 1 |
| Chon, JS | 1 |
| Frosch, DL | 2 |
| Martin, JM | 2 |
| Norris, K | 1 |
| Sardu, C | 4 |
| D'Onofrio, N | 3 |
| Torella, M | 1 |
| Portoghese, M | 2 |
| Loreni, F | 1 |
| Mureddu, S | 1 |
| Signoriello, G | 1 |
| Scisciola, L | 1 |
| Barbieri, M | 3 |
| Rizzo, MR | 3 |
| Galdiero, M | 1 |
| De Feo, M | 1 |
| Balestrieri, ML | 4 |
| Paolisso, G | 3 |
| Marfella, R | 4 |
| Hedrington, MS | 1 |
| Davis, SN | 1 |
| Merino, J | 1 |
| Delahanty, LM | 1 |
| Araneta, MRG | 1 |
| Walford, GA | 1 |
| Jacobs, SBR | 1 |
| Liu, C | 1 |
| Foti, K | 1 |
| Grams, ME | 1 |
| Shin, JI | 1 |
| Selvin, E | 1 |
| Richey, EA | 1 |
| Smith, DS | 1 |
| Carris, NW | 2 |
| Nwabuobi, CK | 1 |
| He, W | 1 |
| Bullers, K | 1 |
| Wilson, RE | 1 |
| Louis, JM | 1 |
| Magness, RR | 2 |
| Madsen, KS | 1 |
| Chi, Y | 1 |
| Metzendorf, MI | 1 |
| Richter, B | 1 |
| Hemmingsen, B | 1 |
| Wolnowska, M | 1 |
| Vadini, F | 2 |
| Simeone, PG | 3 |
| Boccatonda, A | 1 |
| Guagnano, MT | 3 |
| Liani, R | 2 |
| Tripaldi, R | 2 |
| Di Castelnuovo, A | 3 |
| Cipollone, F | 2 |
| Consoli, A | 3 |
| Santilli, F | 3 |
| Ferreira-Hermosillo, A | 1 |
| Molina-Ayala, MA | 1 |
| Molina-Guerrero, D | 1 |
| Garrido-Mendoza, AP | 1 |
| Ramírez-Rentería, C | 1 |
| Mendoza-Zubieta, V | 1 |
| Espinosa, E | 1 |
| Mercado, M | 1 |
| Jinawong, K | 3 |
| Wongsuchai, S | 1 |
| Orioli, L | 1 |
| Hermans, MP | 1 |
| Thissen, JP | 1 |
| Maiter, D | 1 |
| Vandeleene, B | 1 |
| Yombi, JC | 1 |
| Rodríguez, LA | 1 |
| Barquera, S | 1 |
| Aguilar-Salinas, CA | 1 |
| Sepúlveda-Amor, J | 1 |
| Sánchez-Romero, LM | 1 |
| Denova-Gutiérrez, E | 1 |
| Balderas, N | 1 |
| Moreno-Loaeza, L | 1 |
| Handley, MA | 1 |
| Basu, S | 1 |
| López-Arellano, O | 1 |
| Gallardo-Hernández, A | 1 |
| Schillinger, D | 2 |
| Warrilow, A | 1 |
| Somerset, S | 1 |
| Pumpa, K | 1 |
| Fleet, R | 1 |
| Palacios, T | 1 |
| Vitetta, L | 1 |
| Coulson, S | 1 |
| Madigan, CD | 1 |
| Lam, YY | 1 |
| Manuel, R | 1 |
| Briskey, D | 1 |
| Hendy, C | 1 |
| Kim, JN | 1 |
| Ishoey, T | 1 |
| Soto-Giron, MJ | 1 |
| Schott, EM | 1 |
| Toledo, G | 1 |
| Caterson, ID | 1 |
| Szkróbka, W | 4 |
| Bednarska-Czerwińska, A | 1 |
| Rendell, M | 1 |
| Marx, N | 1 |
| Grant, PJ | 1 |
| Davidson, MB | 1 |
| Chang, MS | 1 |
| Hartman, RI | 1 |
| Xue, J | 1 |
| Giovannucci, EL | 1 |
| Nan, H | 1 |
| Yang, K | 1 |
| Ratner, RE | 1 |
| Tao, T | 1 |
| Zhu, YC | 1 |
| Fu, JR | 1 |
| Wang, YY | 1 |
| Cai, J | 1 |
| Ma, JY | 1 |
| Gao, YN | 1 |
| Sun, Y | 1 |
| Fan, W | 1 |
| Liu, W | 1 |
| Wiggers, H | 1 |
| Køber, L | 1 |
| Gislason, G | 1 |
| Schou, M | 1 |
| Poulsen, MK | 1 |
| Vraa, S | 1 |
| Nielsen, OW | 1 |
| Bruun, NE | 1 |
| Nørrelund, H | 1 |
| Hollingdal, M | 1 |
| Barasa, A | 1 |
| Bøttcher, M | 1 |
| Dodt, K | 1 |
| Hansen, VB | 1 |
| Nielsen, G | 1 |
| Knudsen, AS | 1 |
| Lomholdt, J | 1 |
| Mikkelsen, KV | 1 |
| Jonczy, B | 1 |
| Brønnum-Schou, J | 1 |
| Poenaru, MP | 1 |
| Abdulla, J | 1 |
| Raymond, I | 1 |
| Mahboubi, K | 1 |
| Sillesen, K | 1 |
| Serup-Hansen, K | 1 |
| Madsen, JS | 1 |
| Kristensen, SL | 1 |
| Larsen, AH | 1 |
| Bøtker, HE | 1 |
| Torp-Petersen, C | 1 |
| Eiskjær, H | 1 |
| Møller, J | 1 |
| Hassager, C | 1 |
| Steffensen, FH | 1 |
| Bibby, BM | 1 |
| Refsgaard, J | 1 |
| Høfsten, DE | 1 |
| Mellemkjær, S | 1 |
| Gustafsson, F | 1 |
| Htet, TD | 1 |
| Godneva, A | 1 |
| Liu, Z | 1 |
| Chalmers, E | 1 |
| Kolobkov, D | 1 |
| Snaith, JR | 1 |
| Richens, R | 1 |
| Toth, K | 1 |
| Danta, M | 1 |
| Hng, TM | 1 |
| Elinav, E | 1 |
| Segal, E | 1 |
| Greenfield, JR | 2 |
| Samocha-Bonet, D | 2 |
| Færch, K | 2 |
| Blond, MB | 2 |
| Bruhn, L | 2 |
| Amadid, H | 3 |
| Vistisen, D | 2 |
| Clemmensen, KKB | 2 |
| Vainø, CTR | 1 |
| Pedersen, C | 1 |
| Tvermosegaard, M | 1 |
| Dejgaard, TF | 1 |
| Karstoft, K | 3 |
| Ried-Larsen, M | 3 |
| Persson, F | 3 |
| Jørgensen, ME | 3 |
| Holst, JJ | 1 |
| Wewer Albrechtsen, NJ | 1 |
| Torekov, SS | 1 |
| Quist, JS | 1 |
| Faerch, K | 1 |
| Pongkan, W | 1 |
| Jaiwongkam, T | 2 |
| Tokuda, M | 1 |
| Meyers, AG | 1 |
| Hudson, J | 1 |
| Cravalho, CKL | 1 |
| Matta, ST | 1 |
| Villalobos-Perez, A | 1 |
| Cogen, F | 1 |
| Chung, ST | 1 |
| Sosibo, AM | 1 |
| Huang, H | 1 |
| Lorenz, BR | 1 |
| Zelmanovitz, PH | 1 |
| Chan, CB | 1 |
| Alrawashdeh, AY | 1 |
| Al Shhab, MA | 1 |
| Zihlif, MA | 1 |
| Speaker, SL | 1 |
| Rastogi, R | 1 |
| Sussman, TA | 1 |
| Hu, B | 1 |
| Misra-Hebert, AD | 1 |
| Rothberg, MB | 1 |
| Diener, C | 1 |
| Reyes-Escogido, ML | 1 |
| Jimenez-Ceja, LM | 1 |
| Matus, M | 1 |
| Gomez-Navarro, CM | 1 |
| Chu, ND | 1 |
| Zhong, V | 1 |
| Tejero, ME | 1 |
| Alm, E | 1 |
| Resendis-Antonio, O | 1 |
| Guardado-Mendoza, R | 1 |
| Olchanski, N | 1 |
| van Klaveren, D | 1 |
| Cohen, JT | 1 |
| Wong, JB | 1 |
| Ruthazer, R | 1 |
| Kent, DM | 1 |
| Zhou, X | 2 |
| Siegel, KR | 1 |
| Ng, BP | 1 |
| Jawanda, S | 1 |
| Proia, KK | 1 |
| Zhang, X | 1 |
| Albright, AL | 1 |
| Zhang, P | 1 |
| Tabesh, M | 1 |
| Hachem, M | 1 |
| Lau, LH | 1 |
| Borschmann, K | 1 |
| Churilov, L | 1 |
| Price, SAL | 1 |
| Sumithran, P | 1 |
| Donnan, G | 1 |
| Zajac, J | 1 |
| Thijs, V | 1 |
| Ekinci, EI | 1 |
| Grotts, J | 1 |
| Gamede, M | 1 |
| Mabuza, L | 1 |
| Lee, E | 1 |
| Mostafa, TM | 1 |
| Hegazy, SK | 1 |
| Elnaidany, SS | 1 |
| Shehabeldin, WA | 1 |
| Sawan, ES | 1 |
| Trotta, MC | 1 |
| Pieretti, G | 2 |
| Gatta, G | 1 |
| Ferraro, G | 1 |
| Nicoletti, GF | 1 |
| D' Onofrio, N | 1 |
| D' Amico, M | 1 |
| Abbatecola, A | 1 |
| Ferraraccio, F | 1 |
| Panarese, I | 1 |
| Sutkowska, E | 2 |
| Fortuna, P | 2 |
| Kałuża, B | 1 |
| Sutkowska, K | 2 |
| Wiśniewski, J | 2 |
| Prof, AG | 1 |
| Hodurek, P | 1 |
| Gamian, A | 1 |
| Kaluza, B | 1 |
| Maskarinec, G | 1 |
| Raquinio, P | 1 |
| Kristal, BS | 1 |
| Setiawan, VW | 1 |
| Wilkens, LR | 1 |
| Franke, AA | 1 |
| Lim, U | 1 |
| Le Marchand, L | 1 |
| Randolph, TW | 1 |
| Lampe, JW | 1 |
| Hullar, MAJ | 1 |
| Man, B | 1 |
| Schwartz, A | 1 |
| Pugach, O | 1 |
| Xia, Y | 1 |
| Gerber, B | 1 |
| Matić, A | 1 |
| Vuković, R | 1 |
| Heffer, M | 1 |
| Balog, M | 1 |
| Ivić, V | 1 |
| Gaspar, R | 1 |
| Ducza, E | 1 |
| Szucs, KF | 1 |
| Seres, A | 1 |
| Vari, SG | 1 |
| Drenjančević, I | 1 |
| DI Giuseppe, G | 1 |
| Ciccarelli, G | 1 |
| Cefalo, CM | 1 |
| Cinti, F | 1 |
| Moffa, S | 1 |
| Impronta, F | 1 |
| Capece, U | 1 |
| Pontecorvi, A | 1 |
| Giaccari, A | 1 |
| Mezza, T | 1 |
| Desideri, G | 1 |
| Ciotti, S | 1 |
| Tartaro, A | 2 |
| Singhanat, K | 1 |
| Miklankova, D | 1 |
| Markova, I | 1 |
| Hüttl, M | 1 |
| Zapletalova, I | 1 |
| Poruba, M | 1 |
| Malinska, H | 1 |
| Bravard, A | 1 |
| Gérard, C | 1 |
| Defois, C | 1 |
| Benoit, B | 1 |
| Makki, K | 1 |
| Meugnier, E | 1 |
| Rainteau, D | 1 |
| Rieusset, J | 1 |
| Godet, M | 1 |
| Vidal, H | 1 |
| Kominato, H | 1 |
| Takeda, K | 1 |
| Mizutani, K | 1 |
| Mikami, R | 1 |
| Kido, D | 1 |
| Buranasin, P | 1 |
| Saito, N | 1 |
| Takemura, S | 1 |
| Nakagawa, K | 1 |
| Nagasawa, T | 1 |
| Iwata, T | 1 |
| Jensterle, M | 1 |
| Goricar, K | 1 |
| Janez, A | 1 |
| Hafez, D | 1 |
| Nelson, DB | 1 |
| Martin, EG | 1 |
| Cohen, AJ | 1 |
| Northway, R | 1 |
| Maki, DG | 1 |
| Viskochil, R | 1 |
| Malin, SK | 2 |
| Blankenship, JM | 1 |
| Braun, B | 2 |
| Nouhjah, S | 1 |
| Shahbazian, H | 1 |
| Shahbazian, N | 1 |
| Jahanshahi, A | 1 |
| Jahanfar, S | 1 |
| Cheraghian, B | 1 |
| Wang, Z | 1 |
| Xu, D | 1 |
| Huang, L | 1 |
| Zhang, T | 1 |
| Wang, J | 1 |
| Chen, Q | 1 |
| Kong, L | 1 |
| Nielsen, LB | 1 |
| Maniar, K | 1 |
| Moideen, A | 1 |
| Bhattacharyya, R | 1 |
| Banerjee, D | 1 |
| Aroda, VR | 3 |
| Edelstein, SL | 2 |
| Jeffries, SL | 1 |
| Molitch, ME | 1 |
| Pi-Sunyer, X | 1 |
| Darwin, C | 1 |
| Heckman-Stoddard, BM | 1 |
| Nathan, DM | 1 |
| Barrett-Connor, E | 3 |
| Hamman, RF | 3 |
| Mather, KJ | 1 |
| Alnasrallah, B | 1 |
| Pilmore, H | 1 |
| Manley, P | 1 |
| Leo, M | 1 |
| Maccarone, MT | 1 |
| Sborgia, C | 1 |
| Bonadonna, RC | 1 |
| Angelucci, E | 1 |
| Federico, V | 1 |
| Cianfarani, S | 1 |
| Manzoli, L | 1 |
| Davì, G | 1 |
| Roberts, S | 2 |
| Barry, E | 2 |
| Craig, D | 1 |
| Airoldi, M | 1 |
| Bevan, G | 1 |
| Greenhalgh, T | 2 |
| Khokhar, A | 1 |
| Umpaichitra, V | 1 |
| Chin, VL | 1 |
| Perez-Colon, S | 1 |
| Bulatova, N | 1 |
| Kasabri, V | 1 |
| Qotineh, A | 1 |
| Al-Athami, T | 1 |
| Yousef, AM | 1 |
| AbuRuz, S | 1 |
| Momani, M | 1 |
| Zayed, A | 1 |
| Allin, KH | 1 |
| Tremaroli, V | 1 |
| Caesar, R | 1 |
| Jensen, BAH | 1 |
| Damgaard, MTF | 1 |
| Bahl, MI | 1 |
| Licht, TR | 1 |
| Hansen, TH | 1 |
| Nielsen, T | 1 |
| Dantoft, TM | 1 |
| Linneberg, A | 1 |
| Jørgensen, T | 1 |
| Vestergaard, H | 1 |
| Kristiansen, K | 1 |
| Hansen, T | 1 |
| Bäckhed, F | 1 |
| Pedersen, O | 1 |
| Alfawaz, HA | 1 |
| Wani, K | 1 |
| Alnaami, AM | 1 |
| Al-Saleh, Y | 1 |
| Aljohani, NJ | 1 |
| Al-Attas, OS | 1 |
| Alokail, MS | 1 |
| Kumar, S | 1 |
| Al-Daghri, NM | 1 |
| López-Jaramillo, P | 1 |
| Calderón, C | 1 |
| Castillo, J | 1 |
| Escobar, ID | 1 |
| Melgarejo, E | 1 |
| Parra, GA | 1 |
| Debs, S | 1 |
| Schmittdiel, JA | 1 |
| Flory, JH | 1 |
| Yeh, J | 1 |
| Karter, AJ | 1 |
| Kruge, LE | 1 |
| Walker, EA | 1 |
| Zhang, Z | 1 |
| Monro, J | 1 |
| Venn, BJ | 1 |
| Armato, JP | 1 |
| DeFronzo, RA | 2 |
| Abdul-Ghani, M | 2 |
| Ruby, RJ | 1 |
| DeBoer, MD | 1 |
| Filipp, SL | 1 |
| Gurka, MJ | 1 |
| Snehalatha, C | 1 |
| Priscilla, S | 1 |
| Nanditha, A | 1 |
| Arun, R | 1 |
| Satheesh, K | 1 |
| Rhee, SY | 1 |
| Chon, S | 1 |
| Ahn, KJ | 1 |
| Woo, JT | 1 |
| Weijers, RNM | 1 |
| Bekedam, DJ | 1 |
| Labovitz, AJ | 1 |
| Moelands, SV | 1 |
| Lucassen, PL | 2 |
| Akkermans, RP | 2 |
| De Grauw, WJ | 2 |
| Van de Laar, FA | 2 |
| Teng, A | 1 |
| Blakely, T | 1 |
| Scott, N | 1 |
| Jansen, R | 1 |
| Masters-Awatere, B | 1 |
| Krebs, J | 1 |
| Oetzel, J | 1 |
| Maple-Brown, LJ | 1 |
| Lindenmayer, G | 1 |
| Barzi, F | 1 |
| Whitbread, C | 1 |
| Connors, C | 1 |
| Moore, E | 1 |
| Boyle, J | 1 |
| Kirkwood, M | 1 |
| Lee, IL | 1 |
| Longmore, D | 1 |
| van Dokkum, P | 1 |
| Wicks, M | 1 |
| Dowden, M | 1 |
| Inglis, C | 1 |
| Cotter, M | 1 |
| Kirkham, R | 1 |
| Corpus, S | 1 |
| Chitturi, S | 1 |
| Thomas, S | 1 |
| O'Dea, K | 1 |
| Zimmet, P | 1 |
| Oats, J | 1 |
| McIntyre, HD | 1 |
| Brown, A | 1 |
| Shaw, JE | 1 |
| Jose, J | 1 |
| Thomas, N | 1 |
| Kulkarni, S | 1 |
| Xavier, D | 1 |
| George, B | 1 |
| Umesh, S | 1 |
| Fathima, S | 1 |
| Bantwal, G | 1 |
| Paolisso, P | 1 |
| Sacra, C | 1 |
| Mauro, C | 1 |
| Minicucci, F | 1 |
| Sasso, FC | 1 |
| Calabrò, P | 1 |
| Ciccarelli, F | 1 |
| Gambardella, A | 1 |
| Passariello, N | 1 |
| Nicoletti, G | 1 |
| Mohan, M | 1 |
| Al-Talabany, S | 1 |
| McKinnie, A | 1 |
| Mordi, IR | 1 |
| Singh, JSS | 1 |
| Gandy, SJ | 1 |
| Baig, F | 1 |
| Hussain, MS | 1 |
| Bhalraam, U | 1 |
| Khan, F | 1 |
| Choy, AM | 1 |
| Matthew, S | 1 |
| Houston, JG | 1 |
| Struthers, AD | 1 |
| George, J | 1 |
| Lang, CC | 1 |
| Pratte, KA | 1 |
| Johnson, A | 1 |
| Beals, J | 1 |
| Bullock, A | 1 |
| Manson, SM | 1 |
| Jiang, L | 1 |
| Brown, SR | 1 |
| Garnett, SP | 4 |
| Gow, M | 3 |
| Ho, M | 3 |
| Baur, LA | 4 |
| Noakes, M | 2 |
| Woodhead, HJ | 2 |
| Broderick, CR | 2 |
| Burrell, S | 1 |
| Chisholm, K | 2 |
| Halim, J | 1 |
| De, S | 2 |
| Steinbeck, K | 2 |
| Ambler, GR | 2 |
| Kohn, MR | 1 |
| Cowell, CT | 4 |
| Gdula-Dymek, A | 1 |
| Schumm-Draeger, PM | 1 |
| Pratley, RE | 1 |
| Sullivan, SD | 1 |
| Kim, C | 2 |
| Christophi, CA | 2 |
| Ratner, R | 2 |
| Gribble, MO | 1 |
| Bennett, WL | 1 |
| Bolen, S | 1 |
| Wilson, LM | 1 |
| Balakrishnan, P | 1 |
| Sahu, A | 1 |
| Bass, E | 1 |
| Kao, WH | 1 |
| Cefalu, WT | 3 |
| van der Aa, MP | 1 |
| Elst, MA | 1 |
| van Mil, EG | 1 |
| Knibbe, CA | 1 |
| van der Vorst, MM | 1 |
| Benitez-Aguirre, PZ | 1 |
| Tam, CS | 1 |
| Donaghue, KC | 1 |
| Craig, ME | 1 |
| Daniele, G | 1 |
| Png, ME | 1 |
| Yoong, JS | 1 |
| Briody, J | 1 |
| Glechner, A | 1 |
| Harreiter, J | 1 |
| Gartlehner, G | 1 |
| Rohleder, S | 1 |
| Kautzky, A | 1 |
| Tuomilehto, J | 2 |
| Van Noord, M | 1 |
| Kaminski-Hartenthaler, A | 1 |
| Kautzky-Willer, A | 1 |
| Cifarelli, V | 1 |
| Lashinger, LM | 1 |
| Devlin, KL | 1 |
| Dunlap, SM | 1 |
| Huang, J | 1 |
| Kaaks, R | 1 |
| Pollak, MN | 1 |
| Hursting, SD | 1 |
| Zhang, C | 2 |
| Zhang, R | 2 |
| Ladeiras-Lopes, R | 1 |
| Fontes-Carvalho, R | 1 |
| Bettencourt, N | 1 |
| Sampaio, F | 1 |
| Gama, V | 1 |
| Leite-Moreira, A | 1 |
| Marrero, DG | 1 |
| Ma, Y | 1 |
| de Groot, M | 1 |
| Horton, ES | 1 |
| Price, DW | 1 |
| Carnethon, MR | 1 |
| Li, J | 1 |
| Ettner, S | 1 |
| Keckhafer, A | 1 |
| Ho, S | 1 |
| de Kreutzenberg, SV | 1 |
| Ceolotto, G | 1 |
| Cattelan, A | 1 |
| Pagnin, E | 1 |
| Mazzucato, M | 1 |
| Garagnani, P | 1 |
| Borelli, V | 1 |
| Bacalini, MG | 1 |
| Franceschi, C | 1 |
| Fadini, GP | 1 |
| Avogaro, A | 1 |
| Oxenkrug, GF | 1 |
| Hostalek, U | 1 |
| Hildemann, S | 1 |
| Gao, F | 1 |
| Zhang, CT | 1 |
| Mayans, L | 1 |
| Provinciali, N | 1 |
| Lazzeroni, M | 1 |
| Cazzaniga, M | 1 |
| Gorlero, F | 1 |
| Dunn, BK | 1 |
| DeCensi, A | 1 |
| Rodriguez-Gutierrez, R | 1 |
| Montori, VM | 1 |
| Perez, A | 2 |
| Alos, VA | 2 |
| Scanlan, A | 1 |
| Maia, CM | 1 |
| Davey, A | 1 |
| Whitaker, RC | 2 |
| Foster, GD | 2 |
| Ackermann, RT | 2 |
| O'Brien, MJ | 2 |
| Mele, L | 1 |
| Orchard, T | 1 |
| Mather, K | 2 |
| Bray, G | 1 |
| Horton, E | 1 |
| Kitabchi, A | 1 |
| Krakoff, J | 1 |
| Marcovina, S | 1 |
| White, N | 1 |
| Konopka, AR | 1 |
| Esponda, RR | 1 |
| Robinson, MM | 1 |
| Johnson, ML | 1 |
| Carter, RE | 1 |
| Schiavon, M | 1 |
| Cobelli, C | 1 |
| Wondisford, FE | 1 |
| Lanza, IR | 1 |
| Nair, KS | 1 |
| Weber, MB | 1 |
| Ranjani, H | 1 |
| Staimez, LR | 1 |
| Anjana, RM | 1 |
| Ali, MK | 1 |
| Narayan, KM | 2 |
| Reddy, BR | 1 |
| Maitra, S | 1 |
| Jhelum, P | 1 |
| Kumar, KP | 1 |
| Bagul, PK | 1 |
| Kaur, G | 1 |
| Banerjee, SK | 1 |
| Kumar, A | 1 |
| Chakravarty, S | 1 |
| Buse, JB | 1 |
| Fleming, GA | 1 |
| Ferrannini, E | 1 |
| Gerstein, HC | 1 |
| Bennett, PH | 1 |
| Raz, I | 1 |
| Rosenstock, J | 1 |
| Drosdzol-Cop, A | 1 |
| Skrzypulec-Plinta, V | 1 |
| Arslan, MS | 1 |
| Tutal, E | 1 |
| Sahin, M | 1 |
| Karakose, M | 1 |
| Ucan, B | 1 |
| Ozturk, G | 1 |
| Cakal, E | 1 |
| Biyikli Gencturk, Z | 1 |
| Ozbek, M | 1 |
| Delibasi, T | 1 |
| Dingle, E | 1 |
| Brar, PC | 1 |
| Oke, J | 1 |
| Vijayaraghavan, S | 1 |
| Normansell, R | 1 |
| Mainous, AG | 1 |
| Tanner, RJ | 1 |
| Scuderi, CB | 1 |
| Porter, M | 1 |
| Carek, PJ | 1 |
| Salimi, Y | 1 |
| Fotouhi, A | 1 |
| Mohammad, K | 1 |
| Mansournia, N | 1 |
| Mansournia, MA | 1 |
| Elkind-Hirsch, KE | 1 |
| Paterson, MS | 1 |
| Seidemann, EL | 1 |
| Gutowski, HC | 1 |
| Tong, YZ | 1 |
| Tong, NW | 1 |
| Teng, WP | 1 |
| Mu, YM | 1 |
| Zhao, JJ | 1 |
| Shan, ZY | 1 |
| Ning, G | 1 |
| Scanlan, AB | 1 |
| Ciolino, JD | 1 |
| Homko, C | 1 |
| Hsueh, WA | 1 |
| Handelsman, Y | 1 |
| Andreadis, EA | 1 |
| Katsanou, PM | 1 |
| Georgiopoulos, DX | 1 |
| Tsourous, GI | 1 |
| Yfanti, GK | 1 |
| Gouveri, ET | 1 |
| Diamantopoulos, EJ | 1 |
| Lily, M | 1 |
| Lilly, M | 1 |
| Godwin, M | 1 |
| Fonseca, VA | 2 |
| Dhar, GC | 1 |
| Dannenbaum, D | 1 |
| Jones, MR | 1 |
| Mudaliar, S | 1 |
| Hernandez-Triana, E | 1 |
| Unnikrishnan, AG | 1 |
| Lai, YL | 1 |
| Abby, SL | 1 |
| Misir, S | 1 |
| Jin, X | 1 |
| Nagendran, S | 1 |
| Rhee, MK | 1 |
| Herrick, K | 1 |
| Ziemer, DC | 1 |
| Vaccarino, V | 1 |
| Weintraub, WS | 1 |
| Kolm, P | 1 |
| Twombly, JG | 1 |
| Phillips, LS | 1 |
| Quinn, SM | 1 |
| Bertram, MY | 1 |
| Lim, SS | 1 |
| Barendregt, JJ | 1 |
| Vos, T | 1 |
| Bestermann, WH | 1 |
| Wan, Q | 1 |
| Wang, F | 2 |
| Guan, Q | 1 |
| Wang, C | 1 |
| Feng, L | 1 |
| Gao, G | 1 |
| Gao, L | 1 |
| Zhao, J | 1 |
| Svacina, S | 1 |
| Kitabchi, AE | 1 |
| Montez, MG | 1 |
| Foulkes, MA | 1 |
| Aguilar, D | 1 |
| Gerber, R | 1 |
| Chipkin, SR | 1 |
| Kelly, AS | 1 |
| Bergenstal, RM | 1 |
| Gonzalez-Campoy, JM | 1 |
| Katz, H | 1 |
| Bank, AJ | 1 |
| Bergman, M | 1 |
| Iannello, S | 1 |
| Camuto, M | 1 |
| Cavaleri, A | 1 |
| Milazzo, P | 1 |
| Pisano, MG | 1 |
| Bellomia, D | 1 |
| Belfiore, F | 1 |
| Rao, SS | 1 |
| Disraeli, P | 1 |
| McGregor, T | 1 |
| Meyers, L | 1 |
| Maji, D | 1 |
| Roy, RU | 1 |
| Mukhopadhyay, P | 1 |
| Chowdhury, S | 1 |
| Chadwick, WA | 1 |
| Roux, S | 1 |
| van de Venter, M | 1 |
| Louw, J | 1 |
| Oelofsen, W | 1 |
| Van de Lisdonk, EH | 1 |
| Choi, SH | 1 |
| Zhao, ZS | 1 |
| Lee, YJ | 1 |
| Kim, SK | 1 |
| Kim, DJ | 1 |
| Ahn, CW | 1 |
| Lim, SK | 1 |
| Lee, HC | 1 |
| Cha, BS | 1 |
| Hanefeld, M | 1 |
| Massi-Benedetti, M | 1 |
| Orsini-Federici, M | 1 |
| Appel, SJ | 1 |
| Giger, JN | 1 |
| Traynor, K | 1 |
| Flórez, H | 2 |
| Casanova, P | 1 |
| Widén, EI | 1 |
| Eriksson, JG | 1 |
| Groop, LC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Exercise Training as a Non-pharmacological Treatment for Metabolic Syndrome and Its Interactions With Subjects Habitual Medications.[NCT03019796] | Early Phase 1 | 40 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Metformin Therapy for Gestational Diabetes - Metabolic Late Effects on Child at 9 Years of Age[NCT02417090] | 173 participants (Actual) | Observational | 2015-05-31 | Completed | |||
| A Pharmacist-Coordinated Implementation of the Diabetes Prevention Program[NCT02384109] | 521 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| A Multicentre, Open-labelled, Randomized, Controlled Study to Evaluate the Efficacy of Metformin in Preventing Diabetes in China.[NCT03441750] | Phase 4 | 1,724 participants (Actual) | Interventional | 2017-04-25 | Completed | ||
| Epicardial Fat Evaluation to Predict Clinical Outcomes in Patients Affected by Coronary Artery Disease and Treated by Coronary Artery Bypass Grafting: Diabetic vs. Non Diabetic Patients, and Incretin Therapy Effect; The EPI.FAT.IN Study[NCT03360981] | Phase 4 | 150 participants (Anticipated) | Interventional | 2017-09-20 | Recruiting | ||
| [NCT00004992] | Phase 3 | 3,234 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| Effectiveness of the Treatment With Dapagliflozin and Metformin Compared to Metformin Monotherapy for Weight Loss on Diabetic and Prediabetic Patients With Obesity Class III[NCT03968224] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2018-07-07 | Recruiting | ||
| Public Healthcare Systems and Diabetes Prevention Among People of Mexican Origin: The PRuDENTE Initiative of Mexico City.[NCT03194009] | 3,060 participants (Anticipated) | Interventional | 2017-08-10 | Recruiting | |||
| Research of Exenatide for Management of Reproductive and Metabolic Dysfunction in Overweight/Obese PCOS Patients With Impaired Glucose Regulation[NCT03352869] | Phase 4 | 183 participants (Actual) | Interventional | 2017-11-28 | Completed | ||
| A Randomized, Double-blind, Placebo Controlled Study (DANHEART): Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) and Metformin in Patients With Chronic Heart Failure and Diabetes or Insulin Resistance - M[NCT03514108] | Phase 4 | 1,500 participants (Anticipated) | Interventional | 2018-03-01 | Recruiting | ||
| Personalised Medicine in Prediabetes - Towards Preventing Diabetes in Individuals at Risk[NCT03558867] | 264 participants (Anticipated) | Interventional | 2018-06-05 | Active, not recruiting | |||
| Effect of Dapagliflozin, Metformin and Physical Activity on Glucose Variability, Body Composition and Cardiovascular Risk in Pre-diabetes[NCT02695810] | Phase 2 | 120 participants (Actual) | Interventional | 2016-02-24 | Completed | ||
| Evaluating the Implementation of the Diabetes Prevention Program in an Integrated Health System[NCT03249077] | 8,198 participants (Actual) | Observational | 2017-07-01 | Completed | |||
| Investigating the Impact of p53 and SIRT1 in the Development of Type 2 DM Through the Treatment of Prediabetic Individuals by Either Nigetella Salivata or Metformin[NCT03925714] | Phase 3 | 90 participants (Anticipated) | Interventional | 2019-04-01 | Recruiting | ||
| The Assessment of the Effect of Metformin and Its Serum Concentration on the Concentration of Substances Associated With the Production of Nitric Oxide in Patients With Impaired Carbohydrate Metabolism[NCT03398356] | Phase 4 | 47 participants (Actual) | Interventional | 2017-10-20 | Completed | ||
| Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity[NCT01960205] | Phase 4 | 80 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | ||
| Diabetes Prevention Program Outcomes Study[NCT00038727] | Phase 3 | 2,779 participants (Actual) | Interventional | 2002-09-30 | Active, not recruiting | ||
| Physiology of Disease Prevention Observational Study in Clinical Practice[NCT03308773] | 5,000 participants (Anticipated) | Observational | 2009-01-05 | Enrolling by invitation | |||
| Hospital-based Diabetes Prevention Study in Korea: A Prospective, Multi-center, Randomized, Open-label Controlled Study[NCT02981121] | Phase 4 | 744 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | ||
| Early Insurgence of Coronary Artery Dysfunction in Prediabetic Patients With Monovessel Non Obstructive Coronary Stenosis May Condition Major Adverse Cardiac Events at 24 Months of Follow up.[NCT03553030] | 172 participants (Actual) | Observational | 2015-01-01 | Completed | |||
| Efficacy of Metformin as add-on Therapy in Non-Diabetic Heart Failure Patients[NCT05177588] | Phase 4 | 70 participants (Actual) | Interventional | 2021-07-21 | Completed | ||
| Beta Cell Restoration Through Fat Mitigation[NCT01763346] | 88 participants (Actual) | Interventional | 2013-06-30 | Completed | |||
| Restoring Insulin Secretion Pediatric Medication Study[NCT01779375] | Phase 3 | 91 participants (Actual) | Interventional | 2013-06-16 | Completed | ||
| Restoring Insulin Secretion Adult Medication Study[NCT01779362] | Phase 3 | 267 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| An Efficacy, Safety and Pharmacokinetic Study on the Short-term and Long-term Use of Metformin in Obese Children and Adolescents[NCT01487993] | Phase 3 | 62 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Implementation of a Pragmatic Approach to Lower Diabetes Mellitus Risk After a Diagnosis of Gestational Diabetes Mellitus[NCT05280496] | Phase 3 | 36 participants (Anticipated) | Interventional | 2022-06-01 | Recruiting | ||
| Effects of Metformin on Longevity Gene Expression and Inflammation and Prediabetic Individuals. A Placebo-controlled Trial[NCT01765946] | Phase 4 | 38 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Effect of the Administration of Melatonin and Metformin on Glycemic Control, Genotoxicity and Cytotoxicity Markers in Patients With Prediabetes: Pilot Study[NCT03848533] | Phase 2 | 42 participants (Anticipated) | Interventional | 2019-08-22 | Recruiting | ||
| The Diabetes Community Lifestyle Improvement Program (D-CLIP): A Translation Randomized Trial of a Culturally Specific Lifestyle Intervention for Diabetes Prevention in India[NCT01283308] | 599 participants (Actual) | Interventional | 2009-05-31 | Completed | |||
| Comparative Effectiveness of Point-of-care Glycosylated Hemoglobin Measurement (POC-A1c) vs the Current Standard Based on Oral Glucose Tolerance Test for Early Detection of Type 2 Diabetes Mellitus (DM2) in Colombia[NCT05440968] | 902 participants (Actual) | Interventional | 2022-06-30 | Active, not recruiting | |||
| Metabolic and Endocrine Effects of Combination of Metformin and DPP-4 Inhibitor Saxagliptin Compared to Saxagliptin or Metformin XR Monotherapy in Patients With PCOS and Impaired Glucose Regulation: A Single-blinded Randomized Pilot Study[NCT02022007] | Phase 3 | 38 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| A Combination of Zinc, Chromium, Vitamin C, and Copper Supplement for Prediabetes Progression: Randomized Controlled-Trial in Jakarta[NCT04511468] | 670 participants (Anticipated) | Interventional | 2021-06-23 | Recruiting | |||
| Screening for Prediabetes and Early Diabetes in Primary Care[NCT00787839] | 1,939 participants (Actual) | Observational | 2009-06-30 | Completed | |||
| Exercise Dose and Metformin for Vascular Health in Adults With Metabolic Syndrome[NCT03355469] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2017-08-07 | Recruiting | ||
| The Effect of Real Time Continuous Glucose Monitoring in Subjects With Pre-diabetes[NCT01741467] | 110 participants (Actual) | Interventional | 2012-05-31 | Completed | |||
| Modulating Endoplasmic Reticulum Stress as a Prophylactic Approach Against Symptomatic Viral Infection[NCT04267809] | Phase 2 | 44 participants (Anticipated) | Interventional | 2021-10-22 | Recruiting | ||
| Metformin Pharmacology in Human Cancers[NCT03477162] | Early Phase 1 | 18 participants (Actual) | Interventional | 2018-05-15 | Terminated (stopped due to Enrollment was closed as efforts had become more challenging, and the lab indicated that they were able to obtain their primary objective with the number that had already been enrolled.) | ||
| The Chronic and Acute Postprandial Vascular Effects of Exenatide vs. Metformin in Abdominally Obese Patients With Impaired Glucose Tolerance[NCT00546728] | Phase 4 | 50 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Nude body weight. Value is the difference between the placebo and antihypertensive medication. (NCT03019796)
Timeframe: Subject tested before and after 4 months of training. At baseline tested with and without medication separated 72 hours. Post training tested with and without medication separated 72 hours.
| Intervention | kg (Mean) | |
|---|---|---|
| BEFORE TRAINING | AFTER TRAINING | |
| MEDICATED | 92.1 | 90.0 |
| PLACEBO | 92.5 | 90.8 |
Determined using a ECG-gated automated sphygmomanometer. Value is the difference between the placebo and antihypertensive medication. (NCT03019796)
Timeframe: Subject tested before and after 4 months of training. At baseline tested with and without medication separated 72 hours. Post training tested with and without medication separated 72 hours.
| Intervention | mmHg (Mean) | |
|---|---|---|
| BEFORE TRAINING | AFTER TRAINING | |
| MEDICATED | 75 | 72 |
| PLACEBO | 79 | 77 |
"Index of cardiorespiratory fitness assessed during an incremental cycle-ergometer test using an indirect calorimetry system.~Value is the difference between the placebo and antihypertensive medication." (NCT03019796)
Timeframe: Subject tested before and after 4 months of training. At baseline tested with and without medication separated 72 hours. Post training tested with and without medication separated 72 hours.
| Intervention | Liters of O2/kg weight/min (Mean) | |
|---|---|---|
| BEFORE TRAINING | AFTER TRAINING | |
| MEDICATED | 2.26 | 2.49 |
| PLACEBO | 2.26 | 2.49 |
"Calculated in grams per min during the incremental cycloergometer test wih the use of indirect calorimetry system.~Value is the difference between the placebo and antihypertensive medication." (NCT03019796)
Timeframe: Subject tested before and after 4 months of training. At baseline tested with and without medication separated 72 hours. Post training tested with and without medication separated 72 hours.
| Intervention | grams/min (Mean) | |
|---|---|---|
| BEFORE TRAINING | AFTER TRAINING | |
| MEDICATED | 0.24 | 0.28 |
| PLACEBO | 0.24 | 0.28 |
Determined using a ECG-gated automated sphygmomanometer. Value is the difference between the placebo and antihypertensive medication. (NCT03019796)
Timeframe: Subject tested before and after 4 months of training. At baseline tested with and without medication separated 72 hours. Post training tested with and without medication separated 72 hours.
| Intervention | mmHg (Mean) | |
|---|---|---|
| BEFORE TRAINING | AFTER TRAINING | |
| MEDICATED | 92 | 89 |
| PLACEBO | 97 | 96 |
Determined using a ECG-gated automated sphygmomanometer. Value is the difference between the placebo and antihypertensive medication. (NCT03019796)
Timeframe: Subject tested before and after 4 months of training. At baseline tested with and without medication separated 72 hours. Post training tested with and without medication separated 72 hours.
| Intervention | mmHg (Mean) | |
|---|---|---|
| BEFORE TRAINING | AFTER TRAINING | |
| MEDICATED | 126 | 124 |
| PLACEBO | 134 | 133 |
ADMA- asymmetric dimethylarginine-serum concentration (NCT03398356)
Timeframe: before study start; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 0.51 | 0.52 | 0.50 |
| Group B | 0.57 | 0.55 | 0.52 |
arginine serum concentration (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 112.18 | 107.72 | 104.72 |
| Group B | 111.72 | 97.69 | 103.76 |
serum concentration of the citrulline (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 21.73 | 25.95 | 26.93 |
| Group B | 28.08 | 27.01 | 29.77 |
DMA- dimethylamine, serum concentration (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 1.71 | 1.63 | 1.62 |
| Group B | 2.07 | 1.89 | 1.84 |
the serum concentration of the studied drug-metformin (NCT03398356)
Timeframe: 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 4.36 | 5.09 | 4.66 |
| Group B | 4.25 | 7.42 | 4.01 |
SDMA-symmetric dimethylarginine-serum concentration (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 0.40 | 0.41 | 0.39 |
| Group B | 0.45 | 0.42 | 0.39 |
Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level >= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose >= 200 mg/dL [11.1 mmol/L], after a 75 gram oral glucose tolerance test (OGTT), and confirmed with a repeat test). (NCT00038727)
Timeframe: Outcomes were assessed from 1996-2008 (approximately 12 years including 6 years of DPP).
| Intervention | diabetes incidence (cases per 100 person (Number) |
|---|---|
| 1 Original Lifestyle | 5.3 |
| 2 Original Metformin | 6.4 |
| 3 Original Placebo | 7.8 |
All cause-mortality through clinic reports and National Death Index search (NCT00038727)
Timeframe: Outcomes were assessed throughout follow-up from 1996 to 2022. National Death Index search conducted in 2019 using early release data as of Dec 2018.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1 Original Lifestyle | 158 |
| 2 Original Metformin | 152 |
| 3 Original Placebo | 143 |
Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on estimated glomerular filtration rate (eGFR by chronic kidney disease (CKD-Epi) equation ) (<45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (> 30mg/gm, confirmed). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | average percentage of participants (Number) |
|---|---|
| 1 Original Lifestyle | 11.3 |
| 2 Original Metformin | 13 |
| 3 Original Placebo | 12.4 |
Measured using coronary artery calcification (CAC). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | CAC geometric mean in AU (Geometric Mean) | |
|---|---|---|
| Men | Women | |
| 1 Original Lifestyle | 70.1 | 6.0 |
| 2 Original Metformin | 40.2 | 6.1 |
| 3 Original Placebo | 63.7 | 5.3 |
HbA1C (NCT01763346)
Timeframe: 24 months
| Intervention | percent of hemoglobin (Mean) |
|---|---|
| Metformin | 5.84 |
| Gastric Banding | 5.73 |
mean plasma C-peptide concentration during clamp steady state, adjusted for mean clamp insulin sensitivity (NCT01763346)
Timeframe: 24 months
| Intervention | (nmol/L) adjusted for M/I (Geometric Mean) |
|---|---|
| Metformin | 3.01 |
| Gastric Banding | 3.19 |
fasting and 2-hour OGTT glucose levels (NCT01763346)
Timeframe: 24 months
| Intervention | mmol/l (Mean) | |
|---|---|---|
| fasting glucose | 2-hour glucose | |
| Gastric Banding | 5.85 | 9.92 |
| Metformin | 5.95 | 10.87 |
First phase response (NCT01779375)
Timeframe: 3-months after a medication washout
| Intervention | nmol/L (Mean) |
|---|---|
| Metformin Alone | 1.11 |
| Glargine Followed by Metformin | 1.12 |
Participants had 12-months of active therapy. Secondary results at the end of active intervention. (NCT01779375)
Timeframe: End of active intervention (Month 12)
| Intervention | x 10-5 mmol/kg/min per pmol/L (Mean) |
|---|---|
| Metformin Alone | 1.52 |
| Glargine Followed by Metformin | 1.93 |
Clamp measure of insulin sensitivity (NCT01779375)
Timeframe: 3-months after a medication washout
| Intervention | x 10-5 mmol/kg/min per pmol/L (Mean) |
|---|---|
| Metformin Alone | 1.48 |
| Glargine Followed by Metformin | 1.70 |
Participants had 12-months of active therapy. Secondary results at the end of active intervention. (NCT01779375)
Timeframe: End of active intervention (Month 12).
| Intervention | nmol/L (Mean) | ||
|---|---|---|---|
| Steady State C-peptide | ACPRmax | ACPRg | |
| Glargine Followed by Metformin | 4.37 | 5.79 | 1.03 |
| Metformin Alone | 4.78 | 6.95 | 1.06 |
Clamp measures of ß-cell response, co-primary outcomes (NCT01779375)
Timeframe: 3-months after medication washout (Month 15)
| Intervention | nmol/L (Mean) | |
|---|---|---|
| Steady State C-peptide | ACPRmax | |
| Glargine Followed by Metformin | 4.18 | 5.95 |
| Metformin Alone | 4.82 | 6.92 |
First phase response from the hyperglycemic clamp (NCT01779362)
Timeframe: 3-months after a medication washout
| Intervention | nmol/L (Geometric Mean) |
|---|---|
| Metformin Alone | 1.68 |
| Glargine Followed by Metformin | 1.68 |
| Placebo | 1.68 |
| Liraglutide + Metformin | 1.68 |
Clamp measure of insulin sensitivity (NCT01779362)
Timeframe: 3-months after a medication washout
| Intervention | x 10-5 mmol/kg/min per pmol/L (Geometric Mean) |
|---|---|
| Metformin Alone | 3.53 |
| Glargine Followed by Metformin | 3.38 |
| Placebo | 3.63 |
| Liraglutide + Metformin | 3.49 |
Participants had 12-months of active therapy. Secondary results at the end of active intervention. (NCT01779362)
Timeframe: Secondary analysis was on all participants with a Month 12 visit.
| Intervention | nmol/L (Geometric Mean) | ||
|---|---|---|---|
| ACRPg | Steady State C-peptide | ACRPmax | |
| Glargine Followed by Metformin | 1.88 | 11.6 | 14.1 |
| Liraglutide + Metformin | 2.68 | 21.2 | 10.1 |
| Metformin Alone | 1.93 | 11.7 | 13.4 |
| Placebo | 1.69 | 10.8 | 13.6 |
Clamp measures of ß-cell response, co-primary outcomes (NCT01779362)
Timeframe: 3-months after medication washout (Month 15)
| Intervention | nmol/L (Geometric Mean) | |
|---|---|---|
| Steady State C-peptide | ACPRmax | |
| Glargine Followed by Metformin | 3.58 | 4.32 |
| Liraglutide + Metformin | 3.73 | 4.58 |
| Metformin Alone | 3.65 | 4.61 |
| Placebo | 3.60 | 4.45 |
Height and weight measurements were used to calculate body mass index (BMI), defined as kg/m2. (NCT02022007)
Timeframe: 16 weeks
| Intervention | kg/mg2 (Mean) |
|---|---|
| Metformin XR | 42 |
| Saxagliptin | 36.7 |
| Saxagliptin-Metformin XR | 42 |
Post-treatment fasting glucose levels (NCT02022007)
Timeframe: 16 weeks
| Intervention | mmol/L (Mean) |
|---|---|
| Metformin XR | 5.4 |
| Saxagliptin | 5.3 |
| Saxagliptin-Metformin XR | 5.0 |
Hyperandrogenism is measured by a combination of total testosterone (T) and sex hormone binding globulin (SHBG). The FAI was calculated as the quotient 100 x T/SHBG; hyperandrogenism was defined by a FAI value >3.85. (NCT02022007)
Timeframe: 16 weeks
| Intervention | index (Mean) |
|---|---|
| Metformin XR | 6.3 |
| Saxagliptin | 5.5 |
| Saxagliptin-Metformin XR | 4.3 |
Glucose metabolic secretory status after drug treatment (normal, impaired or diabetic). We used the American Diabetes Association (ADA) definition of impairment which is fasting glucose greater than 100 mg/dL and/or 2 hour glucose greater than 140 mg/dL. (NCT02022007)
Timeframe: 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Metformin XR | 3 |
| Saxagliptin | 6 |
| Saxagliptin-Metformin XR | 10 |
Post-treatment insulin sensitivity index. The Matsuda index of whole-body insulin sensitivity is calculated from an oral glucose tolerance test (10,000/square root of [fasting glucose x fasting insulin] x [mean glucose x mean insulin during OGTT]), and is highly correlated with the rate of whole-body glucose disposal during the euglycemic insulin clamp (NCT02022007)
Timeframe: 16 weeks
| Intervention | Index (Mean) |
|---|---|
| Metformin XR | 2.5 |
| Saxagliptin | 3.5 |
| Saxagliptin-Metformin XR | 4.1 |
Post-treatment mean blood glucose levels. Mean blood glucose (MBG) concentrations were calculated by summing glucose values obtained at 0,30,60 and 120 minutes during the OGTT and dividing by 4. (NCT02022007)
Timeframe: 16 weeks
| Intervention | mmol/L (Mean) |
|---|---|
| Metformin XR | 7.9 |
| Saxagliptin | 7.1 |
| Saxagliptin-Metformin XR | 6.2 |
The number of menstrual cycles during the previous year was recorded and the average menstrual interval calculated by dividing 365 by the number of menstrual cycles in the previous year . During the study period, the patients in a menstrual diary recorded vaginal bleeding over 16 weeks. The effects of treatment intervention on menstrual cycle interval was calculated evaluated by dividing 112 days by the number of menstrual cycles recorded in each patient's menstrual cycle diary. (NCT02022007)
Timeframe: 16 weeks
| Intervention | days between menstrual cycles (Mean) |
|---|---|
| Metformin XR | 81 |
| Saxagliptin | 58 |
| Saxagliptin-Metformin XR | 36 |
The safety criteria will include laboratory values for liver enzymes and document the absence of pregnancy in all participants during the trial (NCT02022007)
Timeframe: 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Metformin XR | 0 |
| Saxagliptin | 0 |
| Saxagliptin-Metformin XR | 0 |
Post-treatment in insulin-sensitivity-secretion index . The insulin secretion-sensitivity index (IS-SI) provides an estimate of β-cell compensation relative to the prevailing insulin resistance, not absolute insulin secretion. It is derived by applying the concept of the disposition index (DI) to measurements obtained during the 2-h OGTT. The IS-SI, a surrogate measure of the DI derived from the OGTT (IGI multiplied by the SIOGTT], was calculated as the product of acute β-cell response [IGI] and Matsuda index (SIOGTT) based on the existence of the predicted hyperbolic relationship between these two measures (NCT02022007)
Timeframe: 16 weeks
| Intervention | index (Mean) |
|---|---|
| Metformin XR | 208 |
| Saxagliptin | 359 |
| Saxagliptin-Metformin XR | 532 |
Post-treatment corrected early phase insulin secretion index (IGI/HOMA-IR). . Early pancreatic β-cell response is estimated as the insulinogenic index (IGI) derived from the ratio of the increment of insulin to that of glucose 30 minutes after a glucose load (insulin 30 min - insulin 0 min/glucose 30 min - glucose 0 min) corrected for by the relative level of insulin resistance (IGI/HOMA-IR which is estimated by homeostasis model assessment of insulin resistance using fasting insulin and glucose levels). (NCT02022007)
Timeframe: 16 weeks
| Intervention | Ratio (Mean) |
|---|---|
| Metformin XR | 0.46 |
| Saxagliptin | 1.4 |
| Saxagliptin-Metformin XR | 1.03 |
The measure of TRG levels and HDL- cholesterol levels are used as an estimate of insulin sensitivity. A TRG/HDL-C ratio of greater than 3.0 is used as an indirect measure of insulin resistance (NCT02022007)
Timeframe: 16 weeks
| Intervention | Ratio (Mean) |
|---|---|
| Metformin XR | 4.2 |
| Saxagliptin | 2.9 |
| Saxagliptin-Metformin XR | 3.0 |
The circumference measurement was taken in the upright position using a 15-mm width flexible metric tape held close to the body but not tight enough to indent the skin. Waist circumference (WC) was measured in centimeters at the narrowest level midway between the lowest ribs and the iliac crest. (NCT02022007)
Timeframe: 16 weeks
| Intervention | centimeters (Mean) |
|---|---|
| Metformin XR | 109 |
| Saxagliptin | 99.6 |
| Saxagliptin-Metformin XR | 106 |
"Area under ROC curve (AROC) for prediction of diabetes (based on OGTT) and high-risk dysglycemia (based on OGTT, IGT with 2 hour OGTT glucose 140-199 mg/dl, and/or IFG with fasting glucose 110-125 mg/dl).~ROC curves are plots of (1-sensitivity) vs. (1-specificity) for all possible screening cutoffs, so a higher AROC indicates higher predictive accuracy. A perfect test would have an AROC of 1.00, while a test equivalent to tossing a coin (random) would have an AROC of 0.50; if confidence limits include 0.50, predictive accuracy is no better than chance.~It is important to appreciate that while AROC analysis can show the relative accuracy of different screening tests, and aid the selection of which test to use in clinical practice, such an analysis does not define what the optimal screening test cutoff is. Selection of the optimal cutoff generally requires consideration of other factors, such as costs and/or the clinical importance of having higher or lower sensitivity." (NCT00787839)
Timeframe: 3 years
| Intervention | area under ROC curve (Number) |
|---|---|
| GCTpl - Diabetes | .85 |
| GCTcap - Diabetes | .82 |
| RPG - Diabetes | .76 |
| RCG - Diabetes | .72 |
| A1c - Diabetes | .67 |
| GCTpl - Dysglycemia | .76 |
| GCTcap - Dysglycemia | .73 |
| RPG - Dysglycemia | .66 |
| RCG - Dysglycemia | .64 |
| A1c - Dysglycemia | .63 |
Cost was expressed as cost (dollars) to identify a single case, with cases defined as (i) diabetes or (ii) high-risk dysglycemia. Cost projections for screening were conducted from both Medicare and VA perspectives. All screening projections assumed follow-up testing with an OGTT if the screening test exceeded a 70% specificity cut-off. (NCT00787839)
Timeframe: 3 years
| Intervention | Dollars (Number) |
|---|---|
| GCTpl - Diabetes - VA | 100 |
| GCTcap - Diabetes - VA | 93 |
| GCTpl - Dysglycemia - VA | 42 |
| GCTcap - Dysglycemia - VA | 37 |
| GCTpl - Diabetes - Medicare | 133 |
| GCTcap - Diabetes - Medicare | 125 |
| GCTpl - Dysglycemia - Medicare | 55 |
| GCTcap - Dysglycemia - Medicare | 50 |
To determine the concentration of metformin in adipose tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 70 |
To determine the concentration of metformin in plasma. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 450 |
To determine the concentration of metformin in tumor-adjacent normal tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 749 |
To determine the concentration of metformin in whole blood. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 514 |
To determine the intra-tumor concentrations of metformin, with a standard deviation ≤25% of the mean, in patients with solid tumors of thoracic origin administered metformin extended release. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 1290 |
Change in reactive hyperemic index over the 3-month treatment period, which is a measure of endothelial (inner lining of blood vessels) function. This is measured as a ratio of post-occlusion blood flow volume versus baseline blood flow volume in fingertips. Higher ratio values are considered indicative of better arterial health. (NCT00546728)
Timeframe: Change from baseline to 3 months
| Intervention | ratio (Mean) |
|---|---|
| Exenatide | 0.01 |
| Metformin | -0.17 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
46 reviews available for metformin and Prediabetes
| Article | Year |
|---|---|
Considering metformin as a second-line treatment for children and adolescents with prediabetes.
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Life Style; Metfor | 2022 |
Vascular complications in prediabetes and type 2 diabetes: a continuous process arising from a common pathology.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Metf | 2022 |
Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adolescent; Advisory Committees; Child; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Mass | 2022 |
The National Clinical Care Commission Report to Congress: Leveraging Federal Policies and Programs to Prevent Diabetes in People With Prediabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucose; Humans; Medicare; Metfor | 2023 |
Diagnosis and Management of Prediabetes: A Review.
Topics: Adult; Blood Glucose; Cardiometabolic Risk Factors; Diabetes Mellitus; Female; Glycated Hemoglobin; | 2023 |
Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type | 2019 |
Review of Prediabetes and Hypertensive Disorders of Pregnancy.
Topics: Blood Glucose Self-Monitoring; Diet Therapy; Exercise; Female; Glycated Hemoglobin; Humans; Hyperten | 2021 |
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Me | 2019 |
COVID-19 in diabetic patients: Related risks and specifics of management.
Topics: Acidosis, Lactic; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Critical Illness; | 2020 |
Pharmacotherapeutic options for prediabetes.
Topics: Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Metformin; | 2021 |
Risk of Skin Cancer Associated with Metformin Use: A Meta-Analysis of Randomized Controlled Trials and Observational Studies.
Topics: Diabetes Mellitus, Type 2; Humans; Metformin; Observational Studies as Topic; Prediabetic State; Ran | 2021 |
Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review.
Topics: Adult; Aged; Community Networks; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Endocrinology; He | 2020 |
Prediabetes: how pathophysiology drives potential intervention on a subclinical disease with feared clinical consequences.
Topics: Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Metformin; Prediabetic State; Sodium-Glucose | 2021 |
Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Prediabetic State | 2017 |
Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Prediabetic State | 2017 |
Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Prediabetic State | 2017 |
Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Prediabetic State | 2017 |
Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Humans; Life Style; Metformin; Prediabetic State; | 2017 |
Metformin Use in Children and Adolescents with Prediabetes.
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pediatric Obes | 2017 |
Prediabetes in Colombia: Expert Consensus.
Topics: Cardiovascular Diseases; Colombia; Consensus; Diabetes Mellitus, Type 2; Disease Progression; Humans | 2017 |
Prevention and Treatment of Type 2 Diabetes: A Pathophysiological-Based Approach.
Topics: Animals; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Genomics; Humans; Metformin; Predia | 2018 |
Review of Metformin Use for Type 2 Diabetes Prevention.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemi | 2018 |
Metformin in Prevention of Type 2 Diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Pr | 2018 |
The Metformin Paradox.
Topics: Blood Glucose; Cell Membrane; Diabetes Mellitus, Type 2; Disease Progression; Erythrocyte Membrane; | 2020 |
Prevention of Diabetes Mellitus in Patients With Prediabetes.
Topics: Cost Savings; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Life S | 2019 |
Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
Topics: Acarbose; Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Diet; Exercise; Fasting; Glucose | 2018 |
The pharmacogenetics of type 2 diabetes: a systematic review.
Topics: Acarbose; Biomarkers, Pharmacological; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Humans; | 2014 |
What are the pharmacotherapy options for treating prediabetes?
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance | 2014 |
Sex-specific differences in diabetes prevention: a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Hypoglycemic Agents; Male; Metformin | 2015 |
Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Re | 2015 |
Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Prediabetic State | 2015 |
Metabolic Syndrome: Insulin Resistance and Prediabetes.
Topics: Bariatric Surgery; Diabetes Mellitus, Type 2; Exercise; Feeding Behavior; Humans; Hypoglycemic Agent | 2015 |
Metformin: risk-benefit profile with a focus on cancer.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Incidence; Insulin Resistance; Metformin; Neoplasms; | 2015 |
Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum.
Topics: Adult; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemi | 2016 |
Metformin for prediabetes.
Topics: Clinical Trials as Topic; Humans; Hypoglycemic Agents; Metformin; Prediabetic State | 2016 |
Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Glycated Hemoglobin; H | 2017 |
Approach to the patient with prediabetes.
Topics: Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Agents; Metformin; Prediabetic | 2008 |
Treating prediabetes with metformin: systematic review and meta-analysis.
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dr | 2009 |
Treatment of clinical insulin resistance in children: a systematic review.
Topics: Adolescent; Body Mass Index; Child; Child Nutritional Physiological Phenomena; Exercise; Female; Hum | 2010 |
[Metformin as the first line antidiabetic agent].
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Prediabetic State | 2010 |
Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; | 2012 |
Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Life Style; Metformin | 2013 |
Drug therapy in prediabetes.
Topics: Acarbose; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Hu | 2005 |
Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.
Topics: Acarbose; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Fasting; Glucose Intolerance; | 2006 |
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes.
Topics: Acarbose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Ang | 2007 |
Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; H | 2008 |
The nurse's role in discouraging clinical inertia in diabetes management: optimizing cardiovascular health among African-Americans.
Topics: Black or African American; Blood Glucose Self-Monitoring; Cardiovascular Diseases; Diabetes Mellitus | 2007 |
Identification and treatment of prediabetes to prevent progression to type 2 diabetes.
Topics: Acarbose; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Glucose Intolerance; Glucos | 2007 |
[Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
Topics: Adult; Aged; Chromans; Comorbidity; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing | 1997 |
72 trials available for metformin and Prediabetes
| Article | Year |
|---|---|
One Bout of Resistance Training Does Not Enhance Metformin Actions in Prediabetic and Diabetic Individuals.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic | 2022 |
Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglyc | 2022 |
Metformin with Versus without Concomitant Probiotic Therapy in Newly Diagnosed Patients with Type 2 Diabetes or Prediabetes: A Comparative Analysis in Relation to Glycemic Control, Gastrointestinal Side Effects, and Treatment Compliance.
Topics: Bifidobacterium animalis; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therap | 2022 |
Baseline characteristics of participants in the Pre-Diabetes Interventions and Continued Tracking to Ease-out Diabetes (Pre-DICTED) Program.
Topics: Adult; Diabetes Mellitus; Female; Glucose; Glucose Intolerance; Humans; Male; Metformin; Middle Aged | 2022 |
Study protocol: Behavioral economics and self-determination theory to change diabetes risk (BEST Change).
Topics: Adult; Body Weight; Diabetes Mellitus, Type 2; Economics, Behavioral; Humans; Metformin; Motivation; | 2023 |
Study protocol: Behavioral economics and self-determination theory to change diabetes risk (BEST Change).
Topics: Adult; Body Weight; Diabetes Mellitus, Type 2; Economics, Behavioral; Humans; Metformin; Motivation; | 2023 |
Study protocol: Behavioral economics and self-determination theory to change diabetes risk (BEST Change).
Topics: Adult; Body Weight; Diabetes Mellitus, Type 2; Economics, Behavioral; Humans; Metformin; Motivation; | 2023 |
Study protocol: Behavioral economics and self-determination theory to change diabetes risk (BEST Change).
Topics: Adult; Body Weight; Diabetes Mellitus, Type 2; Economics, Behavioral; Humans; Metformin; Motivation; | 2023 |
Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled t
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; East Asian People; Female; Glucose; Glucose Into | 2023 |
Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial.
Topics: Adolescent; Adult; Blood Glucose; COVID-19; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; | 2023 |
Design and rationale of the myocardial infarction and new treatment with metformin study (MIMET) - Study protocol for a registry-based randomised clinical trial.
Topics: Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Metformin; Multicenter Studies as T | 2023 |
Coronary Artery Calcium and Cognitive Decline in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Calcinosis; Calcium; Calcium, Dietary; Cognitive Dysfunction; Coronary Artery Disease; Corona | 2023 |
Effectiveness of Shared Decision-making for Diabetes Prevention: 12-Month Results from the Prediabetes Informed Decision and Education (PRIDE) Trial.
Topics: Adult; Aged; Decision Making, Shared; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents | 2019 |
Efficacy of metformin in preventing progression to diabetes in a Chinese population with impaired glucose regulation: Protocol for a multicentre, open-label, randomized controlled clinical study.
Topics: Adolescent; Adult; Aged; China; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Male | 2020 |
Interaction Between Type 2 Diabetes Prevention Strategies and Genetic Determinants of Coronary Artery Disease on Cardiometabolic Risk Factors.
Topics: Adult; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus, Type 2; Exercise; Exerci | 2020 |
Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Life Style; Liraglutide; Longitudina | 2020 |
Exercise improves metformin 72-h glucose control by reducing the frequency of hyperglycemic peaks.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Combined Modality Therapy; Diabetes Mellitus, Type 2; | 2020 |
Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial.
Topics: Adult; Benzhydryl Compounds; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 2; Dose-Res | 2020 |
Design of a cluster-randomized trial of the effectiveness and cost-effectiveness of metformin on prevention of type 2 diabetes among prediabetic Mexican adults (the PRuDENTE initiative of Mexico City).
Topics: Adult; Aged; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Humans; Metformin; Mexico; Middle Age | 2020 |
Metformin use in prediabetes: is earlier intervention better?
Topics: Adult; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Insulin; I | 2020 |
Targeting the Intestinal Microbiota to Prevent Type 2 Diabetes and Enhance the Effect of Metformin on Glycaemia: A Randomised Controlled Pilot Study.
Topics: Aged; Bacteroidetes; Blood Glucose; Butyrates; Diabetes Mellitus, Type 2; Fatty Acids, Volatile; Fem | 2020 |
Plasma gonadotropin levels in metformin-treated men with prediabetes: a non-randomized, uncontrolled pilot study.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Gonadotropins; Humans; Hypoglycemic Agents; Hypogon | 2021 |
Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study.
Topics: Adolescent; Adult; Blood Glucose; China; Drug Therapy, Combination; Exenatide; Female; Glucose Intol | 2021 |
The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr
Topics: Aged; Chronic Disease; Denmark; Diabetes Mellitus; Double-Blind Method; Drug Combinations; Female; H | 2021 |
Rationale and design of a randomised controlled trial testing the effect of personalised diet in individuals with pre-diabetes or type 2 diabetes mellitus treated with metformin.
Topics: Adult; Australia; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Diet; Gly | 2020 |
The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Denmark; Exercise; Glucosides; Gl | 2021 |
No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Ther | 2021 |
Feasibility trial of metformin XR in people with pre-diabetes and stroke (MIPPS)-randomised open blinded endpoint controlled trial.
Topics: Adult; Aged; Australia; Delayed-Action Preparations; Feasibility Studies; Female; Headache; Humans; | 2021 |
Nigella sativa as a promising intervention for metabolic and inflammatory disorders in obese prediabetic subjects: A comparative study of Nigella sativa versus both lifestyle modification and metformin.
Topics: Blood Glucose; Humans; Inflammation; Life Style; Metformin; Nigella sativa; Obesity; Plant Preparati | 2021 |
Metformin has no impact on nitric oxide production in patients with pre-diabetes.
Topics: Adult; Arginine; Citrulline; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitr | 2021 |
A clinical diabetes risk prediction model for prediabetic women with prior gestational diabetes.
Topics: Diabetes, Gestational; Female; Glycated Hemoglobin; Humans; Metformin; Prediabetic State; Pregnancy | 2021 |
Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS.
Topics: Adult; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitor | 2017 |
Effects of saxagliptin on glucose homeostasis and body composition of obese patients with newly diagnosed pre-diabetes.
Topics: Adamantane; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Dipeptides; Dipeptidyl-Peptidase | 2017 |
Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).
Topics: Adult; Aged; Benzhydryl Compounds; Body Composition; Body Weight; Cardiovascular Diseases; Denmark; | 2017 |
Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).
Topics: Adult; Aged; Benzhydryl Compounds; Body Composition; Body Weight; Cardiovascular Diseases; Denmark; | 2017 |
Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).
Topics: Adult; Aged; Benzhydryl Compounds; Body Composition; Body Weight; Cardiovascular Diseases; Denmark; | 2017 |
Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).
Topics: Adult; Aged; Benzhydryl Compounds; Body Composition; Body Weight; Cardiovascular Diseases; Denmark; | 2017 |
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS).
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Reducing; Exercise Therapy; Female; F | 2017 |
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS).
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Reducing; Exercise Therapy; Female; F | 2017 |
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS).
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Reducing; Exercise Therapy; Female; F | 2017 |
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS).
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Reducing; Exercise Therapy; Female; F | 2017 |
Protocol for a pilot randomised controlled trial of metformin in pre-diabetes after kidney transplantation: the Transplantation and Diabetes (Transdiab) study.
Topics: Blood Glucose; Glucose Intolerance; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemi | 2017 |
Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.
Topics: Adipocytes; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide | 2017 |
Effect of metformin combined with lifestyle modification versus lifestyle modification alone on proinflammatory-oxidative status in drug-naïve pre-diabetic and diabetic patients: A randomized controlled study.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glycat | 2018 |
Effects of Different Dietary and Lifestyle Modification Therapies on Metabolic Syndrome in Prediabetic Arab Patients: A 12-Month Longitudinal Study.
Topics: Adult; Arabs; Biomarkers; Blood Glucose; Chi-Square Distribution; Diet, Healthy; Exercise; Female; G | 2018 |
Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES).
Topics: Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Hypoglyc | 2018 |
Use of a Metabolic Syndrome Severity
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progress | 2018 |
Use of a Metabolic Syndrome Severity
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progress | 2018 |
Use of a Metabolic Syndrome Severity
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progress | 2018 |
Use of a Metabolic Syndrome Severity
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progress | 2018 |
Hospital-Based Korean Diabetes Prevention Study: A Prospective, Multi-Center, Randomized, Open-Label Controlled Study.
Topics: Adult; Aged; Algorithms; Diabetes Mellitus, Type 2; Early Intervention, Educational; Humans; Hypogly | 2019 |
Effect of intensive lifestyle modification & metformin on cardiovascular risk in prediabetes: A pilot randomized control trial.
Topics: Adult; Blood Glucose; Body Weight; C-Reactive Protein; Cardiovascular Diseases; Carotid Intima-Media | 2018 |
Effects of Metformin Therapy on Coronary Endothelial Dysfunction in Patients With Prediabetes With Stable Angina and Nonobstructive Coronary Artery Stenosis: The CODYCE Multicenter Prospective Study.
Topics: Aged; Angina, Stable; Coronary Angiography; Coronary Stenosis; Coronary Vessels; Endothelium, Vascul | 2019 |
A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial.
Topics: Aged; Body Weight; Coronary Artery Disease; Female; Heart Ventricles; Humans; Hypertrophy, Left Vent | 2019 |
Regression to Normal Glucose Regulation in American Indians and Alaska Natives of a Diabetes Prevention Program.
Topics: Adult; Aged; Alaskan Natives; Blood Glucose; Diabetes Mellitus, Type 2; Exercise; Female; Follow-Up | 2019 |
Optimal macronutrient content of the diet for adolescents with prediabetes; RESIST a randomised control trial.
Topics: Adolescent; Adolescent Behavior; Body Mass Index; Child; Child Behavior; Combined Modality Therapy; | 2013 |
Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance.
Topics: Dose-Response Relationship, Drug; Drug Synergism; Female; Fenofibrate; Fibrinogen; Glucose Intoleran | 2013 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug | 2014 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug | 2014 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug | 2014 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug | 2014 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug | 2014 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug | 2014 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug | 2014 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug | 2014 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug | 2014 |
METFORMIN: an efficacy, safety and pharmacokinetic study on the short-term and long-term use in obese children and adolescents - study protocol of a randomized controlled study.
Topics: Adolescent; Body Composition; Child; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypogly | 2014 |
Effect of fat loss on arterial elasticity in obese adolescents with clinical insulin resistance: RESIST study.
Topics: Absorptiometry, Photon; Adipose Tissue; Adolescent; Body Composition; Child; Diabetes Mellitus, Type | 2014 |
Improved insulin sensitivity and body composition, irrespective of macronutrient intake, after a 12 month intervention in adolescents with pre-diabetes; RESIST a randomised control trial.
Topics: Adolescent; Blood Pressure; Body Composition; Body Mass Index; Child; Combined Modality Therapy; Die | 2014 |
More effective glycaemic control by metformin in African Americans than in Whites in the prediabetic population.
Topics: Adult; Black or African American; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyc | 2015 |
Depressive symptoms, antidepressant medication use, and new onset of diabetes in participants of the diabetes prevention program and the diabetes prevention program outcomes study.
Topics: Adult; Antidepressive Agents; Depression; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Ag | 2015 |
Depressive symptoms, antidepressant medication use, and new onset of diabetes in participants of the diabetes prevention program and the diabetes prevention program outcomes study.
Topics: Adult; Antidepressive Agents; Depression; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Ag | 2015 |
Depressive symptoms, antidepressant medication use, and new onset of diabetes in participants of the diabetes prevention program and the diabetes prevention program outcomes study.
Topics: Adult; Antidepressive Agents; Depression; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Ag | 2015 |
Depressive symptoms, antidepressant medication use, and new onset of diabetes in participants of the diabetes prevention program and the diabetes prevention program outcomes study.
Topics: Adult; Antidepressive Agents; Depression; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Ag | 2015 |
Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes. A randomized controlled trial.
Topics: Aging; AMP-Activated Protein Kinases; Biomarkers; Blood Glucose; Cell Death; Female; Humans; Hypogly | 2015 |
Differential response in levels of high-density lipoprotein cholesterol to one-year metformin treatment in prediabetic patients by race/ethnicity.
Topics: Adult; Black or African American; Cholesterol, HDL; Cohort Studies; Ethnicity; Female; Hispanic or L | 2015 |
The rationale, design, and baseline characteristics of PREVENT-DM: A community-based comparative effectiveness trial of lifestyle intervention and metformin among Latinas with prediabetes.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Community Health Workers; Comparative Effecti | 2015 |
Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program.
Topics: Adiponectin; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Cohort Studies; Combined Modalit | 2016 |
Hyperglucagonemia Mitigates the Effect of Metformin on Glucose Production in Prediabetes.
Topics: Energy Metabolism; Fasting; Glucagon; Glucose; Humans; Insulin; Kinetics; Leucine; Metformin; Predia | 2016 |
The Stepwise Approach to Diabetes Prevention: Results From the D-CLIP Randomized Controlled Trial.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diet; Female; Follow-Up Studies; Glucose I | 2016 |
Sexual Functioning and Depressive Symptoms in Women with Diabetes and Prediabetes Receiving Metformin Therapy: A Pilot Study.
Topics: Adult; Coitus; Depression; Diabetes Mellitus, Type 2; Female; Humans; Metformin; Prediabetic State | 2017 |
Causal Effects of Intensive Lifestyle and Metformin Interventions on Cardiovascular Disease Risk Factors in Pre-Diabetic People: An Application of G-Estimation.
Topics: Adult; Aged; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; D | 2017 |
Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot
Topics: Adamantane; Adiposity; Adolescent; Adult; Androgens; Biomarkers; Blood Glucose; Delayed-Action Prepa | 2017 |
PREVENT-DM Comparative Effectiveness Trial of Lifestyle Intervention and Metformin.
Topics: Female; Glycated Hemoglobin; Hispanic or Latino; Humans; Hypoglycemic Agents; Life Style; Metformin; | 2017 |
Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insul | 2009 |
Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes.
Topics: Adolescent; Adult; Aged; Algorithms; Allylamine; Anticholesteremic Agents; Clinical Trials as Topic; | 2009 |
Regression to normoglycaemia by fenofibrate in pre-diabetic subjects complicated with hypertriglyceridaemia: a prospective randomized controlled trial.
Topics: Adolescent; Adult; Aged; Blood Glucose; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypoglyce | 2010 |
Menopause and risk of diabetes in the Diabetes Prevention Program.
Topics: Adult; Analysis of Variance; Body Mass Index; Combined Modality Therapy; Diabetes Mellitus, Type 2; | 2011 |
Independent and combined effects of exercise training and metformin on insulin sensitivity in individuals with prediabetes.
Topics: Adult; AMP-Activated Protein Kinases; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial.
Topics: Aged; Analysis of Variance; Biomarkers; Blood Glucose; C-Reactive Protein; Endothelium, Vascular; Ex | 2012 |
Haemostatic effects of metformin in simvastatin-treated volunteers with impaired fasting glucose.
Topics: Antigens; Blood Coagulation; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relati | 2012 |
Effects of short-term metformin treatment on insulin sensitivity of blood glucose and free fatty acids.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Fema | 2004 |
Prevention of type 2 diabetes in the prediabetic population.
Topics: Acarbose; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Exercise; Female; Glucose I | 2005 |
Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM.
Topics: Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; | 1992 |
110 other studies available for metformin and Prediabetes
| Article | Year |
|---|---|
Clozapine induces metformin-resistant prediabetes/diabetes that is associated with poor clinical efficacy in patients with early treatment-resistant schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Humans; Metformin; Prediabetic State; Prospective Studies; Schizoph | 2021 |
Use of metformin following a population-level intervention to encourage people with pre-diabetes to enroll in the National Diabetes Prevention Program.
Topics: Adult; Body Mass Index; Diabetes Mellitus, Type 2; Humans; Life Style; Metformin; Prediabetic State | 2021 |
L6H21 protects against cognitive impairment and brain pathologies via toll-like receptor 4-myeloid differentiation factor 2 signalling in prediabetic rats.
Topics: Animals; Brain; Cognitive Dysfunction; Diet, High-Fat; Insulin Resistance; Male; Metformin; Prediabe | 2022 |
Effect of Metformin on Anthropometric Measurements and Hormonal and Biochemical Profile in Patients with Prediabetes.
Topics: Adult; Anthropometry; Biomarkers; Blood Glucose; Female; Glycated Hemoglobin; Hormones; Humans; Hypo | 2021 |
A diagnosis of prediabetes when combined with lifestyle advice and support is considered helpful rather than a negative label by a demographically diverse group: A qualitative study.
Topics: Diabetes Mellitus; Female; Humans; Life Style; Male; Metformin; Prediabetic State; Qualitative Resea | 2022 |
Screening for Prediabetes and Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diabetes, Gestational; Exercise; Female; Humans; Hypoglycemi | 2022 |
Clinical Care Among Individuals with Prediabetes in Primary Care: a Retrospective Cohort Study.
Topics: Adult; Cohort Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Metformin; Pred | 2022 |
Comparison of glucose metabolism and anthropometry in women with previous gestational diabetes treated with metformin vs. insulin: 9-year follow-up of two randomized trials.
Topics: Anthropometry; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; | 2022 |
Association of gene polymorphisms with body weight changes in prediabetic patients.
Topics: Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Genotype; Humans; Metformin; M | 2022 |
Prediabetes: Adherence to Nutrition Visits Decreases HbA1c in Children and Adolescents.
Topics: Adolescent; Blood Glucose; Child; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Ma | 2022 |
Reduced Cytokine Tumour Necrosis Factor by Pharmacological Intervention in a Preclinical Study.
Topics: Animals; Bile Acids and Salts; Diabetes Mellitus, Type 2; Disease Models, Animal; Metformin; Mice; P | 2022 |
Rosuvastatin potentiates the thyrotropin-lowering effect of metformin in men with non-autoimmune subclinical hypothyroidism and prediabetes.
Topics: Adrenocorticotropic Hormone; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoth | 2022 |
Health Beliefs Associated With Metformin Use Among Insured Adults With Prediabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Male; | 2022 |
The use of metformin for type 2 diabetes prevention: Observational multicenter study from Saudi Arabia.
Topics: Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glycated Hemogl | 2022 |
Trends in Metformin Use Among Patients With Prediabetes: 2008-2020.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Prediabetic State | 2023 |
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta | 2022 |
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta | 2022 |
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta | 2022 |
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta | 2022 |
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta | 2022 |
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta | 2022 |
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta | 2022 |
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta | 2022 |
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta | 2022 |
MicroRNAs Associated With Incident Diabetes in the Diabetes Prevention Program.
Topics: Diabetes Mellitus, Type 2; Humans; Metformin; MicroRNAs; Prediabetic State; Risk Factors | 2023 |
MicroRNAs Associated With Incident Diabetes in the Diabetes Prevention Program.
Topics: Diabetes Mellitus, Type 2; Humans; Metformin; MicroRNAs; Prediabetic State; Risk Factors | 2023 |
MicroRNAs Associated With Incident Diabetes in the Diabetes Prevention Program.
Topics: Diabetes Mellitus, Type 2; Humans; Metformin; MicroRNAs; Prediabetic State; Risk Factors | 2023 |
MicroRNAs Associated With Incident Diabetes in the Diabetes Prevention Program.
Topics: Diabetes Mellitus, Type 2; Humans; Metformin; MicroRNAs; Prediabetic State; Risk Factors | 2023 |
Ameliorative Effects of a Rhenium (V) Compound with Uracil-Derived Ligand Markers Associated with Hyperglycaemia-Induced Renal Dysfunction in Diet-Induced Prediabetic Rats.
Topics: Animals; Diabetes Mellitus, Type 2; Diet; Glomerular Filtration Rate; Hyperglycemia; Kidney; Kidney | 2022 |
Ameliorative Effects of a Rhenium (V) Compound with Uracil-Derived Ligand Markers Associated with Hyperglycaemia-Induced Renal Dysfunction in Diet-Induced Prediabetic Rats.
Topics: Animals; Diabetes Mellitus, Type 2; Diet; Glomerular Filtration Rate; Hyperglycemia; Kidney; Kidney | 2022 |
Ameliorative Effects of a Rhenium (V) Compound with Uracil-Derived Ligand Markers Associated with Hyperglycaemia-Induced Renal Dysfunction in Diet-Induced Prediabetic Rats.
Topics: Animals; Diabetes Mellitus, Type 2; Diet; Glomerular Filtration Rate; Hyperglycemia; Kidney; Kidney | 2022 |
Ameliorative Effects of a Rhenium (V) Compound with Uracil-Derived Ligand Markers Associated with Hyperglycaemia-Induced Renal Dysfunction in Diet-Induced Prediabetic Rats.
Topics: Animals; Diabetes Mellitus, Type 2; Diet; Glomerular Filtration Rate; Hyperglycemia; Kidney; Kidney | 2022 |
Identification of Genetic Variation Influencing Metformin Response in a Multiancestry Genome-Wide Association Study in the Diabetes Prevention Program (DPP).
Topics: Diabetes Mellitus, Type 2; Genetic Variation; Genome-Wide Association Study; Humans; Metformin; Poly | 2023 |
Identification of Genetic Variation Influencing Metformin Response in a Multiancestry Genome-Wide Association Study in the Diabetes Prevention Program (DPP).
Topics: Diabetes Mellitus, Type 2; Genetic Variation; Genome-Wide Association Study; Humans; Metformin; Poly | 2023 |
Identification of Genetic Variation Influencing Metformin Response in a Multiancestry Genome-Wide Association Study in the Diabetes Prevention Program (DPP).
Topics: Diabetes Mellitus, Type 2; Genetic Variation; Genome-Wide Association Study; Humans; Metformin; Poly | 2023 |
Identification of Genetic Variation Influencing Metformin Response in a Multiancestry Genome-Wide Association Study in the Diabetes Prevention Program (DPP).
Topics: Diabetes Mellitus, Type 2; Genetic Variation; Genome-Wide Association Study; Humans; Metformin; Poly | 2023 |
Patient and provider prediabetes knowledge, attitudes, and behavior in a large urban family medicine practice.
Topics: Adult; Cross-Sectional Studies; Family Practice; Female; Health Knowledge, Attitudes, Practice; Huma | 2022 |
Weekly Growth Hormone (Lonapegsomatropin) Causes Severe Transient Hyperglycemia in a Child with Obesity.
Topics: Blood Glucose; Child; Diabetes Mellitus; Dwarfism, Pituitary; Glycated Hemoglobin; Human Growth Horm | 2023 |
Non-Nutritive Sweetened Beverages Impair Therapeutic Benefits of Metformin in Prediabetic Diet-Induced Obese Mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Glucose Intolerance; High Fructose Corn Syrup; M | 2023 |
An Expert Group Consensus Statement on "Approach and Management of Prediabetes in India".
Topics: Consensus; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; India; Metformin; Prediabetic State | 2022 |
Do patients with prediabetes managed with metformin achieve better glycaemic control? A national study using primary care medical records.
Topics: Australia; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Glycemic Control; Humans; | 2023 |
Metformin and exercise effects on postprandial insulin sensitivity and glucose kinetics in pre-diabetic and diabetic adults.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Glucose; Humans; Insulin; Insulin Resistance; Kinet | 2023 |
Metformin restores prohormone processing enzymes and normalizes aberrations in secretion of proinsulin and insulin in palmitate-exposed human islets.
Topics: Adolescent; Carboxypeptidase H; Diabetes Mellitus, Type 2; Glucose; Glycated Hemoglobin; Humans; Ins | 2023 |
Should you treat prediabetes? It's complicated.
Topics: Behavior Therapy; Humans; Life Style; Metformin; Prediabetic State | 2023 |
The Effectiveness of Shared Decision-making for Diabetes Prevention: 24- and 36-Month Results From the Prediabetes Informed Decision and Education (PRIDE) Trial.
Topics: Adult; Decision Making; Decision Making, Shared; Humans; Life Style; Metformin; Patient Participatio | 2023 |
Amelioration of perivascular adipose inflammation reverses vascular dysfunction in a model of nonobese prediabetic metabolic challenge: potential role of antidiabetic drugs.
Topics: Adipose Tissue; Animals; Disease Models, Animal; Feeding Behavior; Hypoglycemic Agents; Inflammation | 2019 |
Pericoronary fat inflammation and Major Adverse Cardiac Events (MACE) in prediabetic patients with acute myocardial infarction: effects of metformin.
Topics: Adiponectin; Adipose Tissue; Aged; Biomarkers; Coronary Artery Bypass; Female; Humans; Hypoglycemic | 2019 |
Trends in Self-reported Prediabetes and Metformin Use in the USA: NHANES 2005-2014.
Topics: Adult; Cross-Sectional Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Metformin; Nut | 2020 |
Capsule Commentary on Liu et al., Trends in Self-reported Prediabetes and Metformin Use in the United States: NHANES 2005-2014.
Topics: Humans; Hypoglycemic Agents; Metformin; Nutrition Surveys; Prediabetic State; Self Report; United St | 2020 |
The impact of oral hormonal contraception on metformin action on hypothalamic-pituitary-thyroid axis activity in women with diabetes and prediabetes: A pilot study.
Topics: Adult; Case-Control Studies; Contraceptives, Oral, Hormonal; Diabetes Mellitus, Type 2; Drug Interac | 2020 |
Necrostatin-1 Mitigates Cognitive Dysfunction in Prediabetic Rats With No Alteration in Insulin Sensitivity.
Topics: Animals; Cognitive Dysfunction; Diet, High-Fat; Hippocampus; Imidazoles; Indoles; Insulin Resistance | 2020 |
Prescribing Paradigm Shift? Damned If You Do, Damned If You Don't.
Topics: Cardiology; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucose; Hu | 2020 |
Metformin Should Not Be Used to Treat Prediabetes.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestational; Dia | 2020 |
Metformin Should Be Used to Treat Prediabetes in Selected Individuals.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Prediabetic State | 2020 |
Not only metformin, but also D-allulose, alleviates metabolic disturbance and cognitive decline in prediabetic rats.
Topics: Animals; Cognitive Dysfunction; Diet, High-Fat; Drinking Water; Fructose; Insulin Resistance; Insuli | 2022 |
Metformin treatment and gastrointestinal symptoms in youth: Findings from a large tertiary care referral center.
Topics: Adolescent; Cross-Sectional Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Female; | 2021 |
Pre-diabetes and COVID-19, could we be missing the silent killer?
Topics: Blood Glucose; Comorbidity; COVID-19; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metfor | 2021 |
Metformin Preserves β-Cell Compensation in Insulin Secretion and Mass Expansion in Prediabetic Nile Rats.
Topics: Animals; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Metformi | 2021 |
High Throughput Study for Molecular Mechanism of Metformin Pre-Diabetic Protection via Microarray Approach.
Topics: Animals; Chemoprevention; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Gene Expressio | 2022 |
Treatment of Patients with Prediabetes in a Primary Care Setting 2011-2018: an Observational Study.
Topics: Adult; Diabetes Mellitus; Female; Humans; Metformin; Prediabetic State; Primary Health Care; Retrosp | 2021 |
Progressive Shifts in the Gut Microbiome Reflect Prediabetes and Diabetes Development in a Treatment-Naive Mexican Cohort.
Topics: Bacteria; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; Feces; Gastrointestinal M | 2020 |
Targeting of the diabetes prevention program leads to substantial benefits when capacity is constrained.
Topics: Adult; Cohort Studies; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Health Services Acc | 2021 |
Choice of Intensive Lifestyle Change and/or Metformin after Shared Decision Making for Diabetes Prevention: Results from the Prediabetes Informed Decisions and Education (PRIDE) Study.
Topics: Decision Making, Shared; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Life Style; | 2021 |
Preventing the onset of diabetes-induced chronic kidney disease during prediabetes: The effects of oleanolic acid on selected markers of chronic kidney disease in a diet-induced prediabetic rat model.
Topics: Animals; Biomarkers; Diabetic Nephropathies; Diet; Diet, High-Fat; Dietary Carbohydrates; Glomerular | 2021 |
Diabetes: Screening, Diagnosis, and Prevention of Type 2 Diabetes.
Topics: Adult; Aged; Child; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Mass Screening | 2021 |
MicroRNAs modulation and clinical outcomes at 1 year of follow-up in obese patients with pre-diabetes treated with metformin vs. placebo.
Topics: Diet, Reducing; Follow-Up Studies; Humans; Metformin; MicroRNAs; Obesity; Prediabetic State | 2021 |
Low metformin dose and its therapeutic serum concentration in prediabetes.
Topics: Adult; Biomarkers; Blood Glucose; Chromatography, Liquid; Disease Management; Drug Monitoring; Durat | 2021 |
The gut microbiome and type 2 diabetes status in the Multiethnic Cohort.
Topics: Aged; Bacteria; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Feces; Female; G | 2021 |
Sex differences in oxidative stress level and antioxidative enzymes expression and activity in obese pre-diabetic elderly rats treated with metformin or liraglutide.
Topics: Animals; Antioxidants; Catalase; Female; Glutathione Peroxidase; Liraglutide; Male; Metformin; Obesi | 2021 |
The impact of metformin on prolactin levels in postmenopausal women.
Topics: Aged; Blood Glucose; Body Mass Index; Comorbidity; Estradiol; Estrogen Replacement Therapy; Female; | 2021 |
Insulin resistance and NAFLD may influence memory performance in obese patients with prediabetes or newly-diagnosed type 2 diabetes.
Topics: Age Factors; Blood Glucose; Cognition; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Female; Hum | 2021 |
Necrostatin-1 reduces cardiac and mitochondrial dysfunction in prediabetic rats.
Topics: Animals; Diet, High-Fat; Imidazoles; Indoles; Insulin Resistance; Male; Metformin; Mitochondria, Hea | 2021 |
Metformin Affects Cardiac Arachidonic Acid Metabolism and Cardiac Lipid Metabolite Storage in a Prediabetic Rat Model.
Topics: Animals; Arachidonic Acid; Basal Metabolism; Biomarkers; Cardiotonic Agents; Disease Models, Animal; | 2021 |
Metformin treatment for 8 days impacts multiple intestinal parameters in high-fat high-sucrose fed mice.
Topics: Animals; Diet, Carbohydrate Loading; Dietary Sucrose; Gastrointestinal Microbiome; Hypoglycemic Agen | 2021 |
Metformin accelerates wound healing by Akt phosphorylation of gingival fibroblasts in insulin-resistant prediabetes mice.
Topics: Animals; Diet, High-Fat; Fibroblasts; Gingiva; Glucose; Insulin; Insulin Resistance; Metformin; Mice | 2022 |
Metformin for Prediabetes.
Topics: Humans; Hypoglycemic Agents; Metformin; Prediabetic State | 2017 |
Understanding type 2 diabetes mellitus screening practices among primary care physicians: a qualitative chart-stimulated recall study.
Topics: Aged; Attitude of Health Personnel; Clinical Decision-Making; Diabetes Mellitus, Type 2; Early Diagn | 2017 |
Review: HbA1c has low accuracy for prediabetes; lifestyle programs and metformin reduce progression to T2DM.
Topics: Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Life Style; Metformin; | 2017 |
Exercise training and metformin, but not exercise training alone, decreases insulin production and increases insulin clearance in adults with prediabetes.
Topics: Adult; Combined Modality Therapy; Exercise; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metf | 2017 |
Incidence and Contributing Factors of Persistent Hyperglycemia at 6-12 Weeks Postpartum in Iranian Women with Gestational Diabetes: Results from LAGA Cohort Study.
Topics: Adult; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Diabetes, Gestational; Fasting; Fem | 2017 |
Metformin exerts anti-obesity effect via gut microbiome modulation in prediabetics: A hypothesis.
Topics: Animals; Anti-Obesity Agents; Butyrates; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Hor | 2017 |
Aberrant intestinal microbiota in individuals with prediabetes.
Topics: Aged; Animals; Anthropometry; Biomarkers; Blood Glucose; Case-Control Studies; Denmark; Diabetes Mel | 2018 |
The Effect of Metformin on Serum Gonadotropin Levels in Postmenopausal Women with Diabetes and Prediabetes: A Pilot Study.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gonadotropins; Humans; Hypothalamo-Hypophyse | 2018 |
Carbohydrate Knowledge and Expectations of Nutritional Support among Five Ethnic Groups Living in New Zealand with Pre- and Type 2 Diabetes: A Qualitative Study.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Ethnicity; Female; Focus Grou | 2018 |
What protects against pre-diabetes progressing to diabetes? Observational study of integrated health and social data.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Delivery of Health Care, Integrated; Diabetes Melli | 2019 |
Real-world experience of metformin use in pregnancy: Observational data from the Northern Territory Diabetes in Pregnancy Clinical Register.
Topics: Adult; Australia; Biomarkers; Birth Weight; Blood Glucose; Case-Control Studies; Diabetes Mellitus, | 2019 |
How should one tackle prediabetes in India?
Topics: Cardiovascular Diseases; Humans; India; Life Style; Metformin; Pilot Projects; Prediabetic State; Ri | 2018 |
Abdominal Fat SIRT6 Expression and Its Relationship with Inflammatory and Metabolic Pathways in Pre-Diabetic Overweight Patients.
Topics: Abdominal Fat; Adult; Down-Regulation; Female; Humans; Male; Metformin; Middle Aged; NF-kappa B; Ove | 2019 |
The Impact of Ethinyl Estradiol on Metformin Action on Prolactin Levels in Women with Hyperprolactinemia.
Topics: Adult; Blood Glucose; Case-Control Studies; Contraceptives, Oral, Hormonal; Diabetes Mellitus; Ethin | 2021 |
Should Adults with Prediabetes Be Prescribed Metformin to Prevent Diabetes Mellitus? No: Evidence Does Not Show Improvements in Patient-Oriented Outcomes.
Topics: Diabetes Mellitus, Type 2; Diet Therapy; Exercise; Humans; Hypoglycemic Agents; Metformin; Patient O | 2019 |
Should Adults with Prediabetes Be Prescribed Metformin to Prevent Diabetes Mellitus? Yes: High-Quality Evidence Supports Metformin Use in Persons at High Risk.
Topics: Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Metformin; Patient- | 2019 |
[Early insulin treatment in type 2 diabetes--yes].
Topics: Administration, Oral; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Dia | 2013 |
The early treatment of type 2 diabetes.
Topics: Algorithms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Life Style; Metformin; Practice | 2013 |
Genetic risk of progression to type 2 diabetes and response to intensive lifestyle or metformin in prediabetic women with and without a history of gestational diabetes mellitus.
Topics: Adult; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetes, Gestational; Disease Progression; | 2014 |
A "spoonful of sugar" and the realities of diabetes prevention!
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Life Style; M | 2014 |
Alpha glucosidase inhibitors.
Topics: Acarbose; Diabetes Mellitus; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Humans; Hype | 2014 |
Evaluating the cost-effectiveness of lifestyle modification versus metformin therapy for the prevention of diabetes in Singapore.
Topics: Behavior Therapy; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Health Care Costs; Humans; Hypog | 2014 |
(5) Prevention or delay of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Exercise; Glucose Intolerance; Humans; Hypoglycemic Agents; Metformin; Ob | 2015 |
Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms.
Topics: Animals; Body Weight; Cell Cycle; Diet, Diabetic; Energy Intake; Glucose Intolerance; Hypoglycemic A | 2015 |
Metformin prescription for insured adults with prediabetes from 2010 to 2012: a retrospective cohort study.
Topics: Adult; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Insurance, Health; Life Style; Male; | 2015 |
Increased Plasma Levels of Xanthurenic and Kynurenic Acids in Type 2 Diabetes.
Topics: 3-Hydroxyanthranilic Acid; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agen | 2015 |
Metformin Prescription for Insured Adults With Prediabetes From 2010 to 2012.
Topics: Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Male; Metformin; Prediabetic State | 2015 |
Metformin Prescription for Insured Adults With Prediabetes From 2010 to 2012.
Topics: Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Male; Metformin; Prediabetic State | 2015 |
Sirtuin 1 and 7 mediate resveratrol-induced recovery from hyper-anxiety in high-fructose-fed prediabetic rats.
Topics: Animals; Antioxidants; Anxiety Disorders; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes M | 2016 |
Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes.
Topics: Adult; Blood Glucose; Body Mass Index; Fasting; Female; Humans; Hypoglycemic Agents; Insulin; Insuli | 2017 |
A Neutral Effect of Metformin Treatment on Macroprolactin Content in Women with Macroprolactinemia.
Topics: Adult; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hyperprolactinemia; Metformi | 2017 |
Prediabetes in Obese Adolescents.
Topics: Adolescent; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Life Style; Male; Metfor | 2017 |
Prediabetes Screening and Treatment in Diabetes Prevention: The Impact of Physician Attitudes.
Topics: Adult; Attitude of Health Personnel; Blood Glucose; Diabetes Mellitus; Family Practice; Female; Huma | 2016 |
Consensus on the Prevention of Type 2 Diabetes in Chinese Adults.
Topics: Acarbose; Blood Glucose; Consensus; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Metformi | 2017 |
Pharmacologic treatment options for prediabetes.
Topics: Acarbose; Animals; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Mice; | 2008 |
The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study.
Topics: Body Mass Index; Body Size; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Greece; | 2009 |
Identification and treatment of prediabetes to prevent progression to type 2 diabetes.
Topics: Acarbose; Anti-Obesity Agents; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, | 2008 |
Metformin is a unique drug.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Practice Guid | 2009 |
Addressing metformin.
Topics: Behavior Therapy; Humans; Hypoglycemic Agents; Metformin; Patient Selection; Prediabetic State; Trea | 2009 |
Many Americans have pre-diabetes and should be considered for metformin therapy.
Topics: Cross-Sectional Studies; Diabetes Mellitus; Female; Glucose Intolerance; Humans; Hypoglycemic Agents | 2010 |
Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care.
Topics: Aged; Australia; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet; Exercise; Female; Humans; H | 2010 |
Incorporating practical lifestyle management for obesity.
Topics: Appetite Depressants; Attitude to Health; Bariatric Surgery; Diabetes Mellitus, Type 2; Diet; Exerci | 2010 |
Glycated hemoglobin as a prognostic risk marker in nondiabetic patients after acute myocardial infarction: what now?
Topics: Angioplasty, Balloon, Coronary; Diabetes Mellitus, Type 2; Follow-Up Studies; Forecasting; Glycated | 2011 |
Steps toward the meaningful translation of prevention strategies for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Intention to Treat Analysis; Male; Metformin; Prediabetic | 2012 |
The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
Topics: Adult; Combined Modality Therapy; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Follow-U | 2012 |
The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
Topics: Adult; Combined Modality Therapy; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Follow-U | 2012 |
The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
Topics: Adult; Combined Modality Therapy; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Follow-U | 2012 |
The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
Topics: Adult; Combined Modality Therapy; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Follow-U | 2012 |
The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
Topics: Adult; Combined Modality Therapy; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Follow-U | 2012 |
The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
Topics: Adult; Combined Modality Therapy; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Follow-U | 2012 |
The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
Topics: Adult; Combined Modality Therapy; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Follow-U | 2012 |
The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
Topics: Adult; Combined Modality Therapy; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Follow-U | 2012 |
The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
Topics: Adult; Combined Modality Therapy; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Follow-U | 2012 |
The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
Topics: Adult; Combined Modality Therapy; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Follow-U | 2012 |
The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
Topics: Adult; Combined Modality Therapy; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Follow-U | 2012 |
The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
Topics: Adult; Combined Modality Therapy; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Follow-U | 2012 |
The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
Topics: Adult; Combined Modality Therapy; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Follow-U | 2012 |
The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
Topics: Adult; Combined Modality Therapy; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Follow-U | 2012 |
The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
Topics: Adult; Combined Modality Therapy; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Follow-U | 2012 |
The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
Topics: Adult; Combined Modality Therapy; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Follow-U | 2012 |
Early, aggressive treatment is effective in treating diabetes. Risk of long-term complications reduced significantly.
Topics: Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypog | 2012 |
Impaired glucose tolerance and impaired fasting glucose.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes, Gestational; Disease Progression; Female; Glucose Intole | 2004 |
Research profile. Treating prediabetes. Exercise, metformin, or both? Barry Braun, PhD.
Topics: Exercise; Humans; Hypoglycemic Agents; Metformin; Prediabetic State; United States | 2005 |
Anti-diabetic effects of Sutherlandia frutescens in Wistar rats fed a diabetogenic diet.
Topics: Anesthesia; Animals; Blood Glucose; Body Weight; Diet; Dietary Fats; Glucose; Glycogen; Hyperinsulin | 2007 |
The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Metformin; Pioglita | 2007 |
Diabetes specialists keep ACCORD data in perspective.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glycated | 2008 |
[Changes in clinical intervention studies: when the wellbeing of the patients takes precedence].
Topics: Antihypertensive Agents; Chromans; Clinical Trials as Topic; Diabetes Complications; Enalapril; Ethi | 1998 |